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O número crescente de pessoas afetadas mundialmente pelo cancro tem 
levado a comunidade científica a ampliar os esforços de pesquisa nesta área. 
O desenvolvimento de novos fármacos com potencial aplicação no tratamento 
do cancro tem sido amplamente estudado. Os pirazóis e os seus derivados 
são uma classe promissora devido ao seu variado espectro de atividades, que 
inclui a ação anticancerígena.     
Neste trabalho são preparados derivados de uma família de (E)-3(5)-(2-
hidroxifenil)-4-estiril-1H-pirazóis através de reações de glicosilação ou pela 
formação de complexos de coordenação de ruténio tritiaciclononano, com o 
objetivo de obter novos compostos com ação citotóxica contra células 
tumorais. Os compostos sintetizados são caracterizados recorrendo a técnicas 
espetroscópicas de RMN 1D (1H e 13C) e 2D (HSQC, HMBC, COSY e 
NOESY), espectrometria de massa e espectroscopia de infravermelho no caso 
dos complexos de ruténio. Sempre que possível, a pureza dos compostos foi 
ainda avaliada através da determinação do ponto de fusão.  
Os compostos sintetizados são avaliados contra uma linha celular de cancro 
do estômago (AGS) e contra uma linha celular saudável de fibroblastos do 
pulmão (MRC-5), de modo a averiguar tangencialmente a sua seletividade. 
Dos compostos sintetizados, o mais potente é o complexo de ruténio contendo 
o ligando pirazol com um grupo metoxilo na posição -para- do estirilo. Este 
composto apresentou um IC50 de 18.3 μM contra a linha celular tumoral AGS e 
um IC50 de 62.2 μM contra a linha celular saudável MRC-5. A inserção do 
ligando no complexo de ruténio melhorou a seletividade quando comparada 
com o ligando isolado.   
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The growing number of cancer patients worldwide has led the scientific 
community to strengthen research efforts in this field. The development of 
novel drug candidates for cancer treatment has been largely studied. Among 
these, pyrazoles derivatives are a promising class for their wide range of 
pharmacological activities, including antitumoral action. 
This work describes the preparation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-
pirazole derivatives, either by glycosylation reactions or by the formation of 
ruthenium trithiacyclononane complexes. The new compounds aim at having 
antitumoral activity. Full characterization of the compounds is carried out by 
NMR 1D (1H and 13C) and 2D (HSQC, HMBC, COSY and NOESY) 
spectroscopies and by mass spectrometry. The new ruthenium-pyrazoles are 
also studied by infrared spectroscopy. Whenever appropriate, the purity of the 
synthesized compounds is evaluated by melting point measurements.   
The compounds are evaluated against a gastric cancer cell line (AGS) and 
against a lung fibroblast cell line (MRC-5) to roughly assess their selectivity. 
The most potent compound is the ruthenium complex with the pyrazole having 
a -para-OCH3 substituted styryl. This compound features an IC50 value of 18.3 
μM against the cancer cell line AGS and an IC50 value of 62.2 μM on the 
healthy cell line MRC-5. Furthermore, the selectivity of this complex with this 
ligand is higher in comparison to that of ligand alone.     
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 Preamble 
 This work is divided into five chapters. The first chapter presents a review of the 
reported pyrazole derivatives regarding their cytotoxic activity. Some pyrazole derivatives 
have well-known molecular targets, that are briefly described. The cytotoxic action of the 
most relevant reported pyrazole derivatives against colon, stomach and lung cancer cell 
lines are also presented. This chapter further contemplates the cytotoxic activity of 
ruthenium complexes and the potential benefits of the complexation of pyrazole 
derivatives with Ru(II)([9]aneS3) concerning their cytotoxic action. Chapter two starts by 
presenting the adopted nomenclature for the novel glycosylated products and their 
precursors, followed by a brief description of the synthesis method for these compounds 
and their structural characterization by NMR. Chapter three is devoted to the 
nomenclature, synthetic route and structural characterization of the new pyrazole-
ruthenium complexes.  Chapter four displays the results of the in vitro cytotoxic action of 
the synthesised pyrazole derivatives. Finally, chapter five refers to the materials and 
methods including equipment, reactants, solvents, and the extensive description of the 
protocols herein employed.  
 Objectives 
The main objectives of this work are the synthesis of novel glycosylated (E)-3(5)-
(2-hydroxyphenyl)-4-styryl-1H-pyrazole derivatives and new ruthenium-pyrazole 
complexes and their cytotoxic evaluation on AGS stomach cancer cell line, as well as their 
preliminary safety assessment using the MRC-5 cell line. These goals were achieved by 
carrying out the following steps: (i) synthesis of (E)-3-styryl-4H-chromen-4-ones and (E)-
3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles; (ii) glycosylation of the synthesized (E)-
3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles; (iii) deprotection of the sugar moiety by 
cleavage of the acetyl protecting groups; (iv) complexation of the free pyrazole derivatives 
with  [Ru(II)([9]aneS3)(DMSO)Cl2]; (v) full structural characterization of the novel 
compounds by 1D (1H and 13C) and 2D (HSQC, HMBC, NOESY) NMR, mass 
spectrometry, and high resolution mass spectrometry or elemental analysis; (vi) 
characterization of the ruthenium-pyrazole complexes by infrared; (vii) cytotoxic 
evaluation of the compounds by MTT assays, resorting to AGS and to MRC-5 cell lines. 
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Chapter 1 
 
 
  Introduction 
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Cancer is a major public health problem worldwide, generally affecting more men 
than women.1 This set of pathologies is highly known by the hyper-proliferative activity of  
cells, that is, they have an abnormal and nonstop growth.2 This is attributed to the fact that 
malignant cells ignore the signals sent to trigger their own apoptosis, a deregulation 
associated with mutations in the genes responsible for the control of cell growth and 
proliferation, namely in pro-oncogenes,2 tumor suppressor genes3 and/or DNA repair 
genes. 
Among the different kinds of cancer, lung cancer is the most prevalent type 
globally, with an estimated incidence of approximately 1.8 million cases for both genres in 
2012.1 In fact, statistics show that lung cancer is the deadliest form of cancer, accounting 
for about 1.5 million deaths worldwide in the same period. Concerning Portugal, statistics 
for both genres in 2012 (see Graphic 1.1) reveal that colorectal cancer is the most mortal, 
with an estimated mortality of 3797 cases, followed by lung and stomach cancer with an 
estimated mortality of 3441 and 2285 cases, respectively.  
 
Graphic 1.1 – Estimated mortality cases in Portugal in 2012 for both genres organized by 
descending prevalence. The NHL acronym stands for Non-Hodgkin lymphoma.  
 
 
Statistics provided by DGS (Direção-Geral da Saúde) show that in 2014 colon cancer and 
lung cancer remained the deadliest in Portugal, although the number of lung cancer obits 
surpassed those of colorectal cancer.4 The numbers depicted in the Graphic 1.1 highlight 
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the need of improved chemotherapeutic drugs, which should have lower cytoxicity to 
healthy cells and higher cytotoxicity towards malignant cells.5  
The work presented in this dissertation addresses the challenges in cancer 
chemotherapy by developing new cytotoxic drug candidates. The structures are based on 
3,4-disubstituted pyrazoles, and include glycosylated derivatives and ruthenium-pyrazole 
complexes, and their synthesis and in vitro cytotoxic evaluation is herein presented. 
Several pyrazoles are already reported to feature cytotoxic bioactivity,6,7 as detailed in the 
subsection 1.1. 
1.1. Pyrazole derivatives  
Pyrazole (1H-pyrazole, 1, Figure 1.1) is a five-membered heteroaromatic ring 
containing two nitrogen atoms at positions 1 and 2 and three carbon atoms.8 N-
unsubstituted pyrazoles may present three identical and non-separable tautomers, due to 
rapid interconversion in solution. Usually it is impossible to unequivocally assign the 
proton resonances of the pyrazole core in the proton-nuclear magnetic resonance (1H 
NMR) spectra of these compounds.  
Pyrazole derivatives span a wide range of bioactivities, such as cytotoxic,8 anti-
inflammatory,9 analgesic, antimicrobial,10 antihypertensive and antiviral11 activities.12,13 
The versatility of pyrazole derivatives led to the exploration of their activities in several 
fields, including  medicine, pharmacology and agrochemical industry.10 Celecoxib 2, 
represented in the Figure 1.2, is a noteworthy example of a drug possessing a N-substituted 
pyrazole scaffold that succeeded in the pharmaceutical field.14,15  
 
 
Figure 1.1 – Chemical structures and numbering of pyrazole 1. 
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Figure 1.2 – Chemical structure of the NSAID drugs Celecoxib 2. 
Compound 2 is a nonsteroidal anti-inflammatory drugs (NSAID) that works by inhibiting 
cyclooxygenase-2. Nevertheless, the activity of N-substituted pyrazoles is not restricted to 
the anti-inflammatory action.14,16 Evidence shows that  N-substituted pyrazole derivatives 
have an important role as anti-proliferative,17 autophagy stimulation,18 inhibition of cell 
growth, pro-apoptotic, anti-angiogenic and anti-leukemic drugs.19 Unfortunately, the vast 
majority of the pyrazole derivatives reported so far does not have a specific mechanism of 
activity associated.8,20,21 Still, whenever it’s possible to determine the action mechanism of 
the pyrazole derivative of interest, scientists determine which pyrazole derivative is the 
most effective and they optimize the structure to achieve better bioactivities.7,22 Note also 
that, for a few number of pyrazole derivatives, targets of cytotoxic action have already 
been identified, and these include telomerase,23 CARM17 and Src.24 
1.1.1. Telomerase as a cytotoxic target for pyrazoles 
Telomerase is an enzyme that monitors the stability of the genome by maintaining 
and repairing telomeres, repetitive TTAGGG sequences present at the chromosome’s end. 
Telomerase activity is absent or undetected in the majority of adult human tissues.25,26 The 
limited telomerase action conjugated with the inability of the DNA replication machinery 
to fully copy the telomeres sequences results in a progressive shrinkage of telomeres in a 
normal adult somatic cell whenever cell division occurs. Subsequently, with aging, 
telomeres reach a critical length causing cells to lose their ability to divide which 
ultimately prevents the endless proliferation of somatic cells.27 However, telomerase is 
active in the majority of tumor cells, allowing them to maintain or lengthen telomeres in 
order to remain able to divide virtually indefinitely.28 This is believed to be a critical step 
in carcinogenesis. Targeting telomerase is thus a trending strategy for the development of 
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novel active therapies against malignant cells with minimal toxicity for healthy tissues.29 
The pyrazole derivatives with known telomerase-inhibiting ability are depicted  in the 
Figure 1.3.23,30,31   
 
Figure 1.3 – Structures of the most active pyrazole derivatives against telomerase, reported by Luo 
et al, Wang et al and Shi et al.23,30,31  
 
Compounds 3,23 430 and 531 were tested against telomerase by the modified telomeric 
repeat amplification protocol (TRAP)23,30 or by the TRAP-PCR-ELISA31 protocol. 
Telomerase inhibition IC50 values for compounds 3, 4 and 5 were, respectively, 0.90, 0.98 
and 1.02 μM. All the compounds showed better performance than the reference drugs used 
in the respective studies (see Figure 1.4). Compound 3 was far better than the control, 
ethidium bromide 6, with an IC50 of 2.6 μM,23 and compound 4 was also more potent than 
the control, staurosporine 7, with an IC50 of 9.0 μM.30 Finally, compound 5 also surpassed 
the IC50 value of ethidium bromide, of 2.1 μM in that study.31  
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Figure 1.4 – Representation of ethidium bromide 6 and staurosporine 7.  
 
Compound 4 was also tested against several cancer cell lines, including the gastric cancer 
cell line MGC-803, against which it featured an IC50 value of 2.96 ± 0.15 μM.30 To assess 
its selectivity toward cancer cells, compound 4 was also tested against human normal 
gastric mucosa (GES-1) and human normal hepatocyte (L-02) cell lines, having IC50 values 
of 1.64 ± 0.17 and 1.62 ± 0.24 mM. Further in vivo tests with 4 on mice affected by S180 
or HepG2 tumors revealed that this compound can inhibit the tumor growth of mice 
affected by S180 or HepG2 tumors. Adding to these outstanding results, the administration 
of compound 4 to mice with EAC tumors increased their survival rate. 
 Compounds 3-5 were also studied by molecular docking studies. All were shown to 
bind strongly to the Tert catalytic subunit of telomerase, establishing four to six 
connections of the hydrogen bonds and electrostatic interaction kind.23,30,31 The four 
bridging sites of compound 3 are depicted in the Figure 1.5. 
Compound 4 binds via the coumarin residue with Lys 710 and Lys 902, via pi-
cation interactions, and Val 904 and Pro 929, via hydrophobic interactions. Moreover, one 
aliphatic chain forms a pi-cation interaction with Phe 568, and the dihydropyrazole ring, 
along with benzene ring, make a hydrophobic interaction with Pro 627.  
Compound 5 also has six binding interactions, as depicted in Figure 1.6.31 
 
7 
 
 
 
Figure 1.5 – Interaction diagram of compound 3 with Tert catalytic subunit (PDB ID: 3DU6), 
adapted from Luo et al.23  The labelled circles represent essential amino acid residues at the binding 
site, with purple for those involved in hydrogen bonding, electrostatic or hydrophilic interactions 
and green for those involved in Van der Waals interactions. The orange arrows represent the pi-
cation interactions and the blue arrows represent the hydrogen bond interactions.  
 
 
Figure 1.6 – Interaction diagram of compound 5 with Tert catalytic subunit (PDB ID: 3DU6), 
adapted from Shi et al.31 The orange arrows represent the pi-cation interactions and the blue arrows 
represent the hydrogen bond interactions. The green arrow stands for the interaction between the 
backbone amino groups of Asp 254 and the N atom of the pyrazole scaffold. The green circles 
show the amino acids which participate in the Van der Waals interactions.  
 
  Compounds 323 and 430 share common structural features, both being 
3,5-diarylpyrazoles. The presence of aromatic groups in these positions seem to be 
important for the formation of pi-cation interactions with Tert’s Lys residues.23,30 
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Consequently, variations of pyrazole scaffolds substituted in positions 3 and 5 with 
aromatic groups may be a good start for the design of a novel telomerase inhibitors family. 
1.1.2. Pyrazole derivatives targeting CARM1 
The coactivator-associated arginine methyltransferase 1 (CARM1) is a member of 
the protein arginine methyltransferase (PRMT) family.32 CARM1 can methylate histone 
H3 and p300/CBP, triggering the alteration of chromatin architecture and, therefore, 
influencing the transcriptional initiation.33,34 Whenever CARM1 is recruited to the 
promoter sequences, histone H3 is methylated and chromatin becomes more accessible to 
the transcriptional machinery, ultimately leading to increased gene expression.34  
CARM1 acts as a co-activator of cancer-related proteins such as the nuclear factor kappa B 
(NF-κB)35 and the tumor suppressor protein p53.36 Also, CARM1 is up-regulated in several 
types of cancer, namely, colorectal37 and lung38 cancer. The co-activation of substrates 
linked to tumorigenesis by CARM1 and its overexpression in numerous cancer types 
makes it an interesting chemotherapeutic target. Attempts to find a suitable CARM1 
inhibitor leaned toward small molecules,39,40 including pyrazole derivatives.7,41,42,43 The 
compounds exhibiting the most relevant CARM1 inhibitory action are depicted in the 
Figure 1.7. The IC50 values obtained for compounds 8,
42 943 and 107 were, respectively 
0.04, 0.06 and 0.08 μM. The compounds 8-10 were tested against other PRMT family 
members, namely PRMT1 and PRMT3. Their inhibitory activity was lower against 
PRMT1 and PRMT3, suggesting that compounds 8-10 are selective toward CARM1.  
 
9 
 
  
Figure 1.7 – Selection of pyrazole derivatives with good inhibitory activity against CARM1, 
reported by Purandare et al,7 Huynh et al42 and Therrien et al.43 
 
1.1.3. Pyrazoles as Src inhibitors 
Pro-oncogene tyrosine-protein kinases (Src) are a family of non-receptor tyrosine-
kinases composed by several members, such as, Blk, Fyn, Fgr, Hck, Lyn, Lck, c-Src, Yrk, 
Yes, Brk and Srm.44,45 The Src protein family is involved in many key processes required 
for the modulation of cell behavior and viability, such as, cell adhesion, spreading, 
motility, division, differentiation and apoptosis.46 Furthermore, Src family can 
phosphorylate key molecules involved in tumor invasion and metastasis, which implies a 
role in the conduct of malignant cells.  
The deregulation of Src members is often associated with uncontrolled cell growth and 
differentiation.47 The protein family member c-Src is the most linked to tumorigenesis and 
cancer progression.48 In fact, c-Src is up-regulated in several types of cancer, including 
pancreatic,49 breast,50 ovarian51 and colorectal52 cancer. The Src involvement in oncologic 
diseases triggered the quest for efficient Src family inhibitors.53 Two pyrazolo-pyrimidine 
compounds, 11 and 12 (Figure 1.8), were tested against breast cancer 8701-BC cells, 
characterized by a significant overexpression of c-Src.54 Their IC50 values (expressed as 
the mean ± SEM) were 31.2 ± 0.5 and 38.8 ± 0.5 μM, respectively. The used reference 
10 
 
drug PP2 or 4-amino-1-(tert-butyl)-3-(4-chlorophenyl)-pyrazolo[3,4-d]pyrimidine (13), 
depicted in Figure 1.9, featured an IC50 value of 61.8 ± 4.4 μM under the same 
experimental conditions. Thus, compounds 11 and 12 were much more potent than the 
used reference drug. 
 
 
Figure 1.8 – Pyrazole derivatives 11 and 12, effective in inhibiting cancer cells with c-Src 
overexpression.54  
 
The ability of pyrazolo-pyrimidine to inhibit Src family members Lck and Fyn was 
also determined.24 For that purpose, Lck and Fyn were previously isolated from cells and 
different concentrations of compounds 13 and 14 (see Figure 1.9) were incubated with Lck 
or Fyn and enolase. This way it was possible to evaluate if the compounds could inhibit 
enolase’s tyrosine phosphorylation by Lck or Fyn. IC50 values for compound 13 and 14 
against Lck were, respectively, 4 and 5 nM, and of 5 and 6 nM against Fyn.  
 
 
Figure 1.9 – Structures of two potent inhibitors of Src family, PP2 13 and 14.24 Both exhibited 
outstanding results in  inhibiting the isolated Src protein family members Lck and Fyn. 
Still, the inhibitory action of pyrazole derivatives against isolated Src proteins is 
undermined if further in vitro assays are not performed. In vitro tests resorting to cell lines 
cover more biological features than mere isolated enzymes. Thus, cell lines assays are 
quite popular regarding in vitro cytotoxic tests.  
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1.2. Pyrazoles with cytotoxic activity against tumor cell lines 
Tumor bi-dimensional cell lines are the most commonly used approach to test the 
biological properties of a drug candidate.55 Cultured cells are able to mimic the biological 
properties of the corresponding in vivo cells and to display the same characteristics of the 
pathology under study.56 Over time, cell lines tend to adapt to their culture environment, 
suffering genotypic modifications that often translate into the phenotype, that is, they lose 
some of their in vivo functions and properties.56,55 Moreover, since cell lines lack their in 
vivo neighboring environment and interactions with other cell types, they tend to neglect 
their conduct within the tissue and behave differently in vitro. In vitro experiments will 
always have their setbacks; still, they provide useful information about the drugs’ cytotoxic 
potential. In what concerns N-substituted pyrazole derivatives, growth inhibitory activity 
has already been reported on a few human cancer cell lines, including colon 
adenocarcinoma (HT29),57 lung cancer (NCI-H460),58 gastric cancer (AGS),59 breast 
adenocarcinoma (MCF7),58 ovarian carcinoma (A2780), among others.60 Herein, reports 
on the activity of pyrazole derivatives against lung, colorectal and gastric cancer cell lines 
are presented, as these represent the most deadly types of cancer worldwide.1  
1.2.1. Inhibitory action against human colon cancer cell lines 
Colorectal cancer incidence risk is increased by a poor diet, sedentarism, obesity, 
unbalanced alcohol intake and age.61 The incidence risk is also associated with multiple 
genetic variants identified by the genome-wide association study.62  
Despite the intricate background of this pathology, there are reports of pyrazole 
derivatives possessing good inhibitory action against human colon adenocarcinoma cell 
lines, namely against HCT2957,63 and HCT116 cell lines.64 The most effective 
pyrazoloacridines reported by Antonini et al against HCT29 are compounds 15 and 16 
(represented in the Figure 1.10), with IC50 values of 3.9 and 31.0 nM, respectively.
57 These 
values are nonetheless higher than those of the reference drugs, mitoxantrone (17) and 
doxorubicin (18), with respective IC50 values of 1.0 and 2.6 nM, albeit compound 15 is 
within the same order of magnitude. 
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Figure 1.10 – Structure of the most potent compounds reported by Antonini et al57 (top line) and of 
the reference drugs, mitoxantrone (17) and doxorubicin (18), used in the same study (bottom).  
 
Competitive ethidium bromide displacement indicates that both 15 and 16 have Guanine-
Cytosine as binding site preference. Further modifications on the structure of 15, the one 
with the best performance, may afford some interesting compounds with higher cytotoxic 
activity.  
In another study by Lukasik et al, the synthetized pyrazole derivatives were tested 
against the HCT116 cell line, being compounds 19 and 20 (Figure 1.11) the most efficient 
with GI50 values of 0.49 and 0.59 μM, respectively.64  
 
Figure 1.11 – Structures of the most relevant cytotoxic compounds against HCT-116 cell line  
reported by Lukasik et al.64  
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It is important to mention that the pyrazole derivatives reported by Antonini et al 
and Lukasik et al were not tested against healthy cell lines. Thus, their cytotoxicity towards 
healthy cells is unknown and a selectivity and safety profile remains to be established.  
1.2.2. Pyrazoles active against human lung carcinoma 
Lung cancer was, statistically, the most lethal type of cancer for both sexes 
worldwide, in 2012.1 Among the acknowledged risk factors, cigarette smoking is the most 
relevant one in the development of lung cancer.65 Mutations in the epidermal growth factor 
receptor (EGFR), kirsten rat sarcoma viral oncogene homolog (KRAS), and anaplastic 
lymphoma kinase (ALK) are also risk factors for this pathology.66  
Among the reported drugs possessing in vitro inhibitory action against lung cancer 
cell lines, some tri-substituted pyrazole derivatives featuring a cytotoxic activity against 
lung cancer A549 cell line are of interest.67,68 Two families of tri-substituted pyrazoles, 
reported by Xia et al67 and Lian el al,68 present cytotoxic action against the A549 lung 
cancer cell line. Xia el al study consisted in the synthesis of N-substituted pyrazole 
derivatives67 and, in a follow-up research made by Lian et al, a sugar moiety (a glucosyl or 
a xylosyl unit, depending on the compound) was attached to the previously tested tri-
substituted pyrazole derivatives.68 The mentioned pyrazole derivatives are substituted in 
their pyrazole scaffold at position 1, 3 and 5. Their general structure and IC50 values may 
be consulted in the Table 1.1. Among the compounds without a sugar moiety, compounds 
21 and 25 weren’t active towards A549 cell line.67 Note how the IC50 values of the 
compounds linked to a sugar moiety are, for the majority, lower than the IC50 values 
achieved by their parent compounds.68 The exceptions were compound 26, having a lower 
IC50 value than compounds 32 and 33; and compound 24, having a lower IC50 value than 
compound 31. Altogether, these two studies disclose the cytotoxic benefits employed by 
the attachment of a sugar moiety to a pyrazole scaffold.  
 
 
 
 
 
 
14 
 
Table 1.1 – General structure of the tri-substituted pyrazoles and their glycated derivatives, 
followed by their respective substituents (R1, R2 and R3, being the last one only valid for the 
glycated pyrazoles). The IC50 values against A549 cell line, after 48 hours of compound’s 
incubation, are also presented.  
 
Compound R1 R2 R3 IC50 (μM) 
21 H H − n.d.[a] 
22 H t-Bu − 26.5 
23 Cl H − 38.7 
24 Cl t-Bu − 18.5 
25 OCH3 H − n.d.[a] 
26 OCH3 t-Bu − 23.9 
27 H t-Bu Xylosyl 15.2 
28 H t-Bu Glucosyl 21.6 
29 Cl H Glucosyl 31.8 
30 Cl t-Bu Xylosyl 13.9 
31 Cl t-Bu Glucosyl 26.6 
32 OCH3 t-Bu Xylosyl 24.9 
33 OCH3 t-Bu Glucosyl 38.9 
 
[a] n.d. = not determined. 
1.2.3. Disubstituted pyrazoles active against human gastric adenocarcinoma 
Gastric cancer is directly related to the infectious organism Helicobacter pylori.69 
H. pylori is a risk factor for the development of non-cardia gastric cancer.70 Also, nutrition 
has been implicated in the development of this disease. High consumptions of salt and 
nitrates are associated with a higher risk of gastric cancer development.  
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Despite the intricacy of this multifactorial pathology, there are some promising 
studies showing the cytotoxic activity of pyrazole derivatives against stomach cancer cell 
lines, explicitly against AGS59 and BGC823 cell lines.71,72 In fact, a family of 3,5-diaryl-
1H-pyrazoles studied against the AGS cell line afforded interesting results.59 The structures 
of the mentioned 3,5-diaryl-1H-pyrazoles, numbered from 34 to 36, are represented in the 
Figure 1.12. The type and position of the substituent groups allows to establish structure – 
activity correlations. 
  
 
Figure 1.12 – Structure of a family of 3,5-disubstituted pyrazoles active against stomach cancer 
AGS cells.59  
 
Compound 34, having a 4-methoxyphenyl in position 5 of the pyrazole, is the most active, 
with an GI50 of 0.79 ± 0.08 μM. In turn, when the substituent is a 2-methoxyphenyl 
(compound 35), the activity is lost (no action at the highest concentration tested, 40 μM). 
This shows that the position of the functional group is of high relevance for the cytotoxic 
activity. The type of functional group also plays an important role in the cytotoxic action. 
Compound 36, with a 4-CF3-phenyl in position 5, had a GI50 of 6.9 ± 0.7 μM, which is 
around ninefold higher than that of compound 34. These results point towards the 
relevance of para-substituted aryl groups on cytotoxic action against gastric cancer, further 
suggesting that a methoxy group, with electron-donating properties, contributes to higher 
efficacy.  
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A set of 3-(1H-indole-3-yl)-1H-pyrazole-5-carbohydrazide derivatives were tested 
against the stomach cancer cell line BGC823.71 The structure of the most active 
compounds reported by this study (37 to 39) and the structure of the used reference drug 
(40) are depicted in the Figure 1.13. 
 
Figure 1.13 – Representation of some of the synthetized 3-(1H-indole-3-yl)-1H-pyrazole-5-
carbohydrazide derivatives (37-39) reported by Zhang et al.71 Fluorouracil (40) was used as a 
reference drug.  
 
The IC50 of compounds 37-40 was, respectively, 1.94 ± 0.46, 1.89 ± 0.24, 0.71 ± 0.14 and 
6.15 ± 0.59 μM. Note that 38, with a 4-methoxyphenyl group in the position 1 of the 
pyrazole, had a slightly better activity than 37, which features an aliphatic chain in the 
same position. Still, the highlight goes to 39 with a 4-fluorophenyl in position 1 and 
activity within the nanomolar range. Thus, the family of 3-(1H-indol-3-yl) pyrazole-5-
carbohydrazide has a substituent effect opposite to that of the previously described 3,5-
diaryl-1H-pyrazoles, that is, in this case the activity against stomach cancer is not 
significantly increased by the presence of the -para-OMe group.   
1.3. Ruthenium complexes 
The modification of substituents and their positioning is a widely used strategy for 
attempting to enhance the cytotoxic potential of a certain compound.59,71 Over the years 
several approaches were employed with this same purpose.73,74 One interesting approach is 
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the complexation of ruthenium with organic compounds, aiming at a higher cytotoxic 
activity and a lower toxicity.5 Ruthenium is a transition metal with several possible 
oxidation states, such as +2 (Ru(II)), +3 (Ru(III)) and, less frequently, +4 (Ru(IV)).75 Of 
these, Ru(IV) is the most unstable and, consequently, the less explored. Ruthenium can 
mimic iron and, therefore, it can attach to plasma proteins like transferrin and albumin.76 
These plasma proteins are responsible for the solubilization and transportation of iron.77 
Therefore, the attachment of ruthenium to transferrin and albumin is deemed to reduce its 
interaction with the healthy tissue when compared to other drugs, such as cisplatin. 
Cisplatin is a platinum-based drug widely used as a chemotherapeutic drug but its 
cytotoxicity towards healthy cells, drug resistance and undesired side effects have limited 
its attractiveness.78 
Some reported ruthenium complexes exhibit excellent cytotoxic activity both in 
vitro and in vivo,79 which highlights their potential to overcome the issues associated with 
cisplatin.80 Indeed, two Ru(III) inorganic complexes have already entered human clinical 
trials: indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)81 and sodium 
trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339), presented in the Figure 
1.14.82 KP1019 is particularly effective towards colorectal cancer cells, as demonstrated by 
in vivo studies in rats. KP1019 decreased the volume of colorectal chemically induced 
tumors.83 Its mechanism of action is based on the induction of malignant cell death by p53-
independent apoptosis. This compound successfully passed phase I clinical trials and the 
phase II trials are still ongoing.84,85 Compound NKP-1339 was shown to be effective in 
vivo against solid tumors, including colorectal carcinoma, non-small cell lung cancer and 
gastrointestinal neuroendocrine tumors.86 NKP-1339 also successfully passed phase I 
clinical trials and it is currently under phase II clinical trials.  
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Figure 1.14 – Structure of KP1019, on the left, and its sodium salt analogue, NKP-1339 on the 
right. 
 
 
1.3.1. Ru(II)[9]aneS3 – pyrazole complexes as chemotherapeutic drugs 
In the literature there is a single published study, reported by Marques et al, on the 
cytotoxic activity of one Ru(II) trithiacyclononane complex bearing a 5-(2-
hydroxyphenyl)-3-[(4-methoxystyryl)pyrazole] as a monodentate ligand (see Figure 
1.15).20 
 
Figure 1.15 – Structure of the Ru(II)([9]aneS3)(5-phpz-OMe)Cl2 complex.  
This Ru-pyrazole derivative complex was evaluated against human prostate 
adenocarcinoma (PC-3) and human breast adenocarcinoma (MDA-MB-231) cell lines. 
Cisplatin was used as control and the free 5-phpz-OMe [(E)-3(5)-(2-hydroxyphenyl)-5(3)-
(4-methoxystyryl)-1H-pyrazole] was used to evaluate if  complexation improved the  
cytotoxic activity. The IC50 values of the free 5-phpz-OMe, Ru(II)([9]aneS3)(5-phpz-
OMe)Cl2 complex and cisplatin were, respectively, 9.9, 32.3 and 6.6 μM, against PC-3 cell 
line. Concerning the MDA-MB-231 cell line, the IC50 values were respectively of 10.2, 
19.2 and 9.5 μM. Note that the cytotoxic action of the free 5-phpz-OMe was comparable to 
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cisplatin, which emphasizes the cytotoxic activity of hydroxyphenylpyrazoles as a class of 
compounds by itself.  
Furthermore, it should be noted that albeit the performance of the complex on these 
cell lines was slightly worse than that of the free 3,5-diarylpyrazole ligand, the 
complexation with Ru(II) is expected to lower the overall toxicity of the pyrazole ligand. 
Thus, additional studies investigating the effect on healthy cells are in need. The studies 
may also be expanded to include a larger variety of cancer cell lines. These results inspired 
us to develop novel 3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles, both in the free form 
and coordinated with Ru(II)([9]aneS3), to learn more about their antitumor potential using 
the AGS cancer cell line.  
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Chapter 2 
 
 
Glycosylation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-
1H-pyrazoles 
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The (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles were prepared from (E)-3-
styryl-4H-chromen-4-ones, as reported by Silva et al (details in sub-chapter 2.2.2.).87  The 
glycosylation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles was performed by the 
Koenigs-Knorr method described in the literature88 (consult sub-chapter 2.2.3.), affording 
novel glycosylated pyrazole derivatives.  
2.1. Nomenclature adopted for the synthesized compounds 
 The adopted nomenclature for the (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-
pyrazoles glycosylated products and its precursors may be consulted in the next sub-
chapters. With exception of the 3-styryl-4H-chromen-4-ones, the nomenclature adopted 
does not follow the IUPAC rules. To simplify, starting from that point the numbering of 
the presented compounds will start from number 1.  
2.1.1. (E)-3-Styryl-4H-chromen-4-ones 
The nomenclature and numbering system adopted for the (E)-3-styryl-4H-chromen-
4-ones 3a-d follows the recommendations of IUPAC89 and the attributed numbering is 
represented in the Figure 2.1. The styryl group at position 3 may be non-substituted R1= R2 
= H, or substituted at ortho- or para- positions of the phenyl ring (R1 = CF3 or R
2 = Cl, 
OCH3). The “(E)” is used to indicate the stereochemistry of the double bond between 
carbons  and . Thus, these compounds will be named as (E)-3-(2-/4-Rstyryl)-4H-
chromen-4-ones 3a-d, where R is the substituent present in the aromatic ring of the styryl 
group. 
 
Figure 2.1 – Structure and numbering system of (E)-3-(2-/4-Rstyryl)-4H-chromen-4-ones 3a-d. 
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2.1.2. (E)-3(5)-(2-Hydroxyphenyl)-4-styryl-1H-pyrazoles 
To facilitate the structural characterization of pyrazoles 4a-d (see Figure 2.2) by 
comparison with data from the literature, the name given to these compounds does not 
follow the IUPAC rules. Instead the nomenclature adopted considers the pyrazole ring as 
the main group which is numbered starting by the NH, while the groups at positions 3 and 
4, respectively, are considered as substituents. The hydrogen at N1 position of tautomer I 
(Figure 2.2) can move to N2 forming the tautomer II of the pyrazole. This effect, known as 
prototropy, occurs in pyrazoles which are non-substituted at N1. Therefore, the position 3 
is indicated as 3(5) considering the possibility of having one or another pyrazole tautomer. 
These compounds will be named as (E)-3(5)-(2-hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-
pyrazoles 4a-d. 
 
Figure 2.2 – Structure and numbering system of (E)-3(5)-(2-hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-
pyrazoles 4a-d. 
 
2.1.3. Pyrazoles containing sugar moieties at position N1 
The nomenclature of the compounds represented in Figure 2.3 does not follow the 
IUPAC rules to facilitate their structural characterization by comparison with the precursor 
compounds, the pyrazoles 4a-d. The pyrazole nucleus is considered the main group which 
is substituted at positions 1, 3 and 4. The sugar unit incorporated in the structure at position 
N1 is numbered using <"'> (see Figure 2.3). Compounds 5a-d, that present the sugar 
moiety linked to the pyrazole through the carbon C-1’’’ will be named as, (E)-1-[β-D-
(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-pyrazole, 
while compounds 6a-d will be named as 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-
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acetoxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-
hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-pyrazole. 
Figure 2.3 – Structure and numbering system of (E)-1-[β-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]- 
3-(2-hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-pyrazoles 5a-d, and 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-
diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-
hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-pyrazole 6a-d. 
 
 
The nomenclature of compounds 7a-d and 8a,b, represented in Figure 2.4, follows 
the same rules as those above mentioned for the pyrazole derivatives 5a-d from which 7a-
d were obtained and for 6a-d from which 8a,b were obtained upon the cleavage of the 
acetyl groups of the sugar moiety.  
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Figure 2.4 – Structure and numbering system of (E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-
4-(2-/4-Rstyryl)-1H-pyrazoles 7a-d and 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-
hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-
(2-/4-Rstyryl)-1H-pyrazoles 8a,b. 
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2.2.  Synthesis 
The methods adopted for the synthesis of the glycosylated compounds and their 
precursors are briefly described. For the detailed experimental protocols on the synthesis of 
these compounds, please refer to the chapter 5.  
2.2.1.  Synthesis of (E)-3-styryl-4H-chromen-4-ones 
The novel (E)-3-(4-methoxystyryl)-4H-chromen-4-one (3d) and the already 
reported (E)-3-styryl-4H-chromen-4-ones 3a and 3b, are obtained through a Knoevenagel-
type condensation followed by in situ decarboxylation of 4-oxo-4H-chromene-3-
carbaldehyde 1 with the appropriate phenylacetic acids in dry pyridine, in the presence of 
potassium tert-butoxide as a base, according to the procedure reported by Silva et al 
(Scheme 2.1).90,91 The (E)-3-styryl-4H-chromen-4-one 3c was already available in the 
laboratory and was previously synthesized following the same procedure. The mechanism 
of this reaction is already described in the literature.91  The (E)-3-styryl-4H-chromen-4-
ones 3a, 3b and 3c were obtained in very good yields (73%, 82% and 91%, respectively). 
The yield of 3d (34%) was lower probably because the pyridine used in the reaction was 
not freshly dried. 
 
Scheme 2.1 – Synthesis of (E)-3-styryl-4H-chromen-4-ones 3a-d. 
 
2.2.2.  Synthesis of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 
 The new (E)-3(5)-(2-hydroxyphenyl)-4-(4-methoxystyryl)-1H-pyrazole (4d) and 
the ones already reported, 4a and 4b, were prepared from the appropriate (E)-3-styryl-4H-
chromen-4-ones by treatment with hydrazine hydrate in methanol at room temperature, 
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following the procedure reported by Silva et al (Scheme 2.2).87 Under such conditions, the 
expected (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 4a, 4b and 4d were obtained 
in very good yields (74-98%). The not yet reported (E)-3(5)-(2-hydroxyphenyl)-4-(2-
trifluoromethylstyryl)-styryl-1H-pyrazole (4c) was already available in the laboratory; it 
was synthesized in very good yield (98%) following the same procedure. 
 
Scheme 2.2 – Synthesis of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 4a-d.  
 
2.2.3.  Novel glycosylated (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles obtained 
by Koenigs-Knorr method 
In a first approach, the glycosylation reaction of (E)-4-(4-chlorostyryl)-3(5)-(2-
hydroxyphenyl)-1H-pyrazole (4b) with 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl 
bromide was performed under molecular sieves (4Å) in dry CH2Cl2 using Ag2CO3 as a 
base and AgOTf as promoter following the Koenigs-Knorr method described in the 
literature.88 After purification of the reaction mixture, by thin layer chromatography using 
CH2Cl2:acetone (9:1) as eluent,  two N-glycosylated products were isolated and 
characterized by 1D and 2D NMR techniques, as well as by mass spectrometry. The 
product with lower r.f. corresponds to compound 5b and the product with higher r.f. to 
compound 6b (Scheme 2.3). Using the same protocol, we carried out the glycosylation of 
the remaining pyrazoles 4a, 4c and 4d, as shown in Scheme 2.3. Different reaction times 
were tested to perceive the influence of this parameter on the yield of the novel products 
5a-d and 6a-d. Table 2.1 presents the reaction time and yields of the products isolated in 
the glycosylation reactions performed in this work. Note that compounds 5d and 6d 
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comprise a mixture of (E)- and (Z)-isomers and, for this, only their 1H NMR spectra were 
collected. These are given in the sub-chapter 5.2.3.  
 
Scheme 2.3 – Koenigs-Knorr glycosylation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 
4a-d.  
 
This glycosylation reaction requires several days to afford products 5 and 6 in 
moderate to good yields, as seen in Table 2.1. The yields show that compound 6 is, in most 
cases, the main reaction product. Yet, the global yield of this reaction seems to be affected 
by the solvent dryness. In fact, the global yield of the reaction decreases when 
dichloromethane is not freshly distilled (see entries 1-4, Table 2.1). The storage of 
dichloromethane in molecular sieves 4Å doesn’t remove the water so efficiently as the 
distillation over calcium hydride. Thus, when the solvent was dried with molecular sieves 
4Å (entries 2 and 4, Table 2.1), there were higher traces of water in the reaction mixture, 
which particularly jeopardized the attained yields for compound 6. These results may 
indicate that compound 6 is more susceptible to degradation in the presence of water. 
Furthermore, the total reaction yield is also affected by the reaction time. To see the effect 
of the reaction time, the substituent effect and solvent drying procedure must be the same 
(see entries 5 and 6, Table 2.1). For these experiments, the total yield was higher when the 
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reaction time was longer. These results indicate that this reaction needs prolonged reaction 
time to achieve a better yield.  
 
Table 2.1 – Reaction time and yields of the Koenigs-Knorr glycosylation of (E)-3(5)-(2-
hydroxyphenyl)-4-styryl-1H-pyrazoles 4a-d. 
Entry R1 R2 
Reaction time 
(days) 
Yield of 5 
(%)[a] 
Yield of 6 
(%)[a] 
Total yield 
(%) 
1[b] H H 7 20 52 72 
2[d] H H 10 21 39 60 
3[c],[b] H Cl 7 19 50 69 
4[d] H Cl 10 25 22 47 
5[d] CF3 H 7 30 6 36 
6[d] CF3 H 10 11 41 52 
7[b] H OMe 7 12 39 51 
[a] Yields of isolated product obtained after purification by thin layer chromatography. [b] Dichloromethane 
was dried over calcium hydride and kept with molecular sieves 4Å. [c] 17% of starting material was 
recovered. [d] Dichloromethane was dried with molecular sieves 4Å without prior distillation over calcium 
hydride. 
 
During a glycosylation reaction there are several factors that may influence the 
obtained products. Among those factors, stereochemistry, neighboring group participation 
and the protecting groups employed at the sugar moiety are of interest. Notice that 
glycosylation is a reaction where a glycosyl donor (a carbohydrate), which behaves as an 
electrophile, is attached to a hydroxyl or other functional group of a glycosyl acceptor, a 
nucleophile, forming a glycoside under appropriate reaction conditions.92 This reaction 
requires the presence of an activator or promoter, such as silver triflate (AgOTf). The 
promoter will aid the departure of the leaving group present in the glycosyl donor (such as 
the Br group), allowing the formation of a reactive intermediate.93 The resulting 
electrophilic anomeric carbon of the glycosyl donor then couples with the glycosyl 
acceptor, forming a glycosidic bond.  
When the glycosyl acceptor attacks the electrophilic anomeric carbon of the 
glycosyl donor, it may be either from the top or the bottom of the sugar ring.93 
Consequently, it’s common to obtain a mixture of products, depending on the possibility of 
having two different stereochemical approaches. The formed linkage may either be axial or 
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equatorial (i.e. α or β, respectively, taking glucose as example). To perceive this, the 
mechanism of a glycosylation reaction is showed in the Scheme 2.4. 
 
 
Scheme 2.4 – General mechanism of the glycosylation reaction; herein P stands for Protecting 
Group and LG stands for Leaving Group. Notice the attack performed by the glycosyl acceptor, 
represented in purple, to the anomeric carbon of the glycosyl donor from either the top (blue arrow) 
or the bottom (green arrow). Adapted from the literature.93 
The stereochemistry of the glycosylated product may also be affected by the type of 
protecting group employed at the C-2 of the glycosyl donor.93 A non-participating group 
usually allows the nucleophilic attack of the glycosyl acceptor either from the bottom or 
top surface. This means that a non-participant group often leads to a mixture of α- and β-
glycosides. However, when a participating group (such as the acetyl group) is involved in 
the glycosylation reaction, the nucleophilic attack of the glycosyl acceptor is limited. 
Consequently, participant groups generally promote the formation of β-glycosides. The 
occurrence of the neighbour group participation in the glycosylation reaction is depicted in 
the Scheme 2.5.  
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Scheme 2.5 – Neighbouring group participation in the glycosylation reaction. The glycosyl 
acceptor is represented in the purple color.  
 
The effect of the protecting groups is not limited to the stereochemistry. In fact, 
protecting groups also play a role in the reactivity of the glycosyl donors.94 Electron-
donating protecting groups, like ether, increase the reactivity of the glycosyl donor. On the 
other hand, electron-withdrawing protecting groups, such as the acetyl group, are 
considered deactivating since they lower the reactivity of the sugar donor. Notice that 
2,3,4,6-tetra-O-acetyl--D-glucopyranosyl bromide, the glycosyl donor used in this work, 
has the acetyl as protecting group; that may be the reason for the need of long reaction 
times observed in the reactions performed. 
The glycosylation reaction mechanisms presented in Schemes 2.4 and 2.5 help to 
understand the reaction mechanisms that lead to the formation of compounds 5a-d and 6a-
d. The proposed mechanisms for the formation of compounds 5a-d and 6a-d may be 
consulted in the Scheme 2.6. 
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Scheme 2.6 – Proposed mechanisms for the formation of compounds 5a-d (represented in green) 
and 6a-d (denoted in blue). The pyrazole derivative is represented in purple. To simplify, the sugar 
moieties of compounds 5a-d and 6a-d are represented as planar structures. 
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2.2.3.1. Removal of the protecting groups of the glycosylated products 
The cleavage of the acetyl protecting groups of the new N-glycosylated compounds 
5a-d and 6a-d was performed following the method reported by Pathak et al, as seen in 
Scheme 2.7.95 To a solution of the appropriate compound 5a-d or 6a-d in methanol was 
added Amberlite® IRA-400(OH) resin as shown in Scheme 2.4. This resin was prepared 
from Amberlite® IRA-400(Cl) resin which was treated with a 1.0 M sodium hydroxide 
solution, washed with water and methanol, thus exchanging the Cl by an OH group. The 
reaction mixture was left at 25-30 ºC with stirring for 4 hours, except for compound 7b 
which reacted for 21 hours to achieve full cleavage of the protecting groups. After that 
period, the reaction mixture was filtered and the resin was washed with methanol. The 
solvent was evaporated to dryness under reduced pressure to afford the novel deprotected 
N-glycosylated products 7a-d and 8a,b. The reaction was not successful for all derivatives. 
In fact, the deprotection of compound 5d leads to a mixture of cis and trans isomers, due to 
the isomerization of the double bound of the styryl group. The deprotection of compound 
6a resulted in modifications of the sugar moiety. Finally, the deprotection reaction of 
compound 6d was not complete; in the 1H NMR spectrum of the reaction product it was 
possible to observe some signals due to the resonance of the acetyl groups of the starting 
material.  
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Scheme 2.7 – Cleavage of the acetyl protecting groups.  
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2.3.  Structural characterization of the synthesised compounds 
The compounds having the chloro as substituent (R2 = Cl) are selected as example 
for structural characterization discussion. The characterization of the (E)-3-(4-
chlorostyryl)-4H-chromen-4-one (3b), already reported by Sandulache et al, won’t be 
presented here.96  
2.3.1.  (E)-3(5)-(2-Hydroxyphenyl)-4-styryl-1H-pyrazoles 
The structural characterization of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-
pyrazoles 4a-d will not be discussed in detail as it is published by Silva et al,87 except for 
compound 4b which was selected as an example, and for the novel compound 4d whose 
full characterization may be consulted in the sub-chapter 5.2.2.  
The 1H NMR spectrum of (E)-4-(4-chlorostyryl)-3(5)-(2-hydroxyphenyl)-1H-
pyrazole (4b) illustrates the various typical signals of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-
1H-pyrazoles (see Figure 2.5).  
 
 
Figure 2.5 – Expansion of the 1H NMR spectrum of (E)-4-(4-chlorostyryl)-3(5)-(2-
hydroxyphenyl)-1H-pyrazole (4b) (CDCl3, 300.13 MHz). 
36 
 
The singlet at  7.85 ppm, due to the resonance of H-5, and the doublets at  7.13 
ppm and  6.84 ppm corresponding to the resonance of protons H-α and H-β are among the 
characteristic signals of these compounds. The coupling constant between H-α and H-β (J 
= 16.4 Hz) indicates a trans configuration of this vinylic system. The resonance of the 2’-
OH proton is also a typical signal of these compounds. However, this is a labile proton 
which in some cases is not observed in the 1H NMR spectrum, as in this example. There 
are also two doublets in the aromatic region, at  7.32 and 7.39 ppm, respectively, due to 
the resonance of the protons H-2’’,6’’ and H-3’’,5’’ of the para-substituted (4-Cl) phenyl 
ring. The other signals in the aromatic region are two doublets of doublets corresponding 
to the resonance of protons H-6’ at  7.58 ppm (J = 7.6, 1.6 Hz) and H-3’ at 7.08 ppm (J = 
8.4, 1.3 Hz), a multiplet due to the resonance of H-4’ at  7.28 – 7.35 ppm and a doublet of 
triplets due to the resonance of H-5’ at  6.97 ppm (J = 7.6, 1.3 Hz).  
Regarding the 13C NMR signals, the spectrum of 4b, on Figure 2.6, also exhibits 
the characteristic resonances of this class of compounds. Among them are the signals due 
to the resonance of the carbons of the pyrazole moiety C-3 ( 148.0 ppm), C-4 ( 120.5 
ppm) and C-5 ( 127.7 ppm). These carbon resonances are assigned based in correlations 
found in the HSQC spectra (H-5 → C-5) and in the HMBC spectra (H-α → C-3 and C-5, 
H-5 → C-3 and C-4, H-6’ → C-3). The resonance of C-2’ is also typical, appearing at high 
frequency values ( 155.6 ppm) since C-2’ is linked to the electronegative oxygen atom of 
the OH group. C-α and C-β are assigned based in the correlations found in the HSQC 
spectra (H-α → C-α, H-β → C-β). The most deprotected carbon corresponds to C-β, 
allowing the unequivocal assignment of the proton and carbon resonances of the vinylic 
system. 
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Figure 2.6 – Expansion of the 13C NMR spectrum of (E)-4-(4-chlorostyryl)-3(5)-(2-
hydroxyphenyl)-1H-pyrazole (4b) (CDCl3, 75.47 MHz). 
 
2.3.2.  (E)-1-[-D-(2,3,4,6-Tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-
1H-pyrazoles 
The structure of the novel (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-
hydroxyphenyl)-4-styryl-1H-pyrazoles 5a-d was elucidated based on 1D (1H and 13C) and 
2D (HSQC, HMBC, COSY and NOESY) NMR spectroscopic experiments. The structure 
of compounds 5a-d was also confirmed by comparing their NMR spectra with those of the 
corresponding (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazole precursor. The most 
characteristic signals in the 1H NMR of compounds 5 appear in the aliphatic region and are 
due to the sugar moiety protons (H-1’’’-H-6’’’) and to the acetyl protecting groups. The 1H 
NMR spectrum example of (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-4-(4-
chlorostyryl)-3-(2-hydroxyphenyl)-1H-pyrazole (5b), is given in the Figure 2.7. 
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Figure 2.7 – 1H NMR spectrum of (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-4-(4-
chlorostyryl)-3-(2-hydroxyphenyl)-1H-pyrazole (5b) [(CD3)2CO, 300.13 MHz].‡  
 
The resonance of H-1’’’, H-2’’’, H-3’’’, H-4’’’, H-5’’’ and H-6’’’ and of the 
protons of the acetyl protecting groups appear at very similar chemical shift values for all 
the compounds 5a-d, as seen in Table 2.2. The resonances of the sugar moiety protons 
were attributed based on the COSY spectra. Typically, there’s a doublet due to the 
resonance of the anomeric proton H-1’’’ at high frequency values,  6.00 – 6.03 ppm, as a 
result of the deshielding effect of the electronegative atoms, with a coupling constant J = 
9.5 Hz for all the derivatives. The value of this coupling constant confirmed the β-
anomeric form of D-glucose in compounds 5. There are three triplets corresponding to the 
resonance of protons H-2’’’ ( 5.78 – 5.83 ppm), H-3’’’ ( 5.55 – 5.56 ppm), and H-4’’’ ( 
5.28 – 5.29 ppm), all having a coupling constant of J = 9.5 Hz in compounds 5a-d. The 
multiplet in the interval of  3.81 – 4.36 ppm is due to the resonance of protons H-5’’’ and 
H-6’’’. Another characteristic of compounds 5a-d is the presence of four singlets ( 1.87 – 
                                                          
‡ The abbreviation “Phpz-Cl” presented in the majority of the spectra refers to the proton or carbon 
resonance signals of the pyrazole moiety. 
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2.10 ppm) corresponding to the resonance of the methyl groups of the acetyl protecting 
groups. The signals due to the resonance of the protons of the pyrazole scaffold (see sub-
chapter 2.3.1) are also observed. 
The most characteristic signals in the 13C NMR spectra of compounds 5a-d are 
ascribed to the resonances of the sugar moiety carbons. The 13C NMR spectrum of (E)-1-
[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)-1H-
pyrazole (5b) is given as example in Figure 2.8. The carbon resonances of both C-1’’’ and 
C-5’’’ appear at higher chemical shifts ( 87.3 and 75.0 ppm, respectively) than C-2’’’ ( 
71.0 – 71.1 ppm), C-3’’’ ( 73.7 ppm), C-4’’’ ( 68.4 – 68.8 ppm) and C-6’’’ ( 62.7 
ppm). Since C-1’’’ and C-5’’’ are linked to two electronegative atoms, they are more 
deprotected than carbons C-2’’’ to C-6’’’. The most protected carbons are -COCH3, 
appearing at  20.2 – 20.6 ppm. The carbon resonances of the four protecting carbonyl 
groups (-COCH3) are highly deshielded, appearing at   169.4 – 170.7 ppm. The fully 
detailed 13C NMR chemical shifts of compounds 5a-d are presented in the experimental 
section – chapter 5. 
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Table 2.2 – Chemical shifts (ppm, relative to TMS) and coupling constants (J, Hz) of 1H NMR 
spectra of (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-1H-
pyrazoles 5a-d.  
          
              Compound          
                     
Signal 
 
5a 5b 5c 5d[a] 
H-5 8.43, s 8.43, s 8.52, s 8.37, s 
2’-OH 9.68, s 9.63, s 9.53, s 9.74, s 
H-3’ 
7.02, dd 
J 7.7, 1.0 
7.00-7.09, m 
7.02, dd 
J 8.0, 1.1 
6.98-7.02, m 
H-4’ 7.27-7.31, m 
7.29, ddd 
J 7.7, 7.9, 1.6 
7.30, ddd 
J 8.0, 7.6, 1.6 
7.26-7.30, m 
H-5’ 
6.98, ddd 
J 7.5, 7.6, 1.0 
6.97, t 
J 7.9 
6.97, dt 
J 7.6, 1.1 
6.94-6.98, m 
H-6’ 
7.64, dd 
J 7.6, 1.6 
7.63, dd 
J 7.9, 1.6 
7.59, dd 
J 7.6, 1.6 
7.65, dd 
J 7.8, 1.6 
H-2’’ 
7.56, d 
J 7.5 
7.58, d 
J 8.2 
− 
7.50, d 
J 8.7 
H-3’’ 
7.38, t 
J 7.5 
7.40, d 
J 8.2 
7.75, d 
J 7.8 
6.95, d 
J 8.7 
H-4’’ 7.27-7.31, m − 
7.50, t 
J 7.8 
− 
H-5’’ 
7.38, t 
J 7.5 
7.40, d 
J 8.2 
7.68, t 
J 7.8 
6.95, d 
J 8.7 
H-6’’ 
7.56, d 
J 7.5 
7.58, d 
J 8.2 
7.96, d 
J 7.8 
7.50, d 
J 8.7 
H-α 
7.21, d 
J 16.3 
7.23, d 
J 16.3 
7.25, d 
J 16.0 
6.98, d[b] 
J 16.2 
H-β 
7.05, d 
J 16.3 
7.04, d 
J 16.3 
7.32, d 
J 16.0 
7.05, d[b] 
J 16.2 
H-1’’’ 
6.02, d 
J 9.5 
6.01, d 
J 9.5 
6.03, d 
J 9.5 
6.00, d 
J 9.5 
H-2’’’ 
5.79, t 
J 9.5 
5.78, t 
J 9.5 
5.83, t 
J 9.5 
5.78, t 
J 9.5 
H-3’’’ 
5.56, t 
J 9.5 
5.55, t 
J 9.5 
5.55, t 
J 9.5 
5.55, t 
J 9.5 
H-4’’’ 
5.29, t 
J 9.5 
5.28, t 
J 9.5 
5.29, t 
J 9.5 
5.29, t 
J 9.5 
H-5’’’ 3.81-4.34, m 4.16-4.36, m 4.19-4.34, m 4.18-4.34, m 
6’’’-CH2OCOCH3 3.81-4.34, m 4.16-4.36, m 4.19-4.34, m 4.18-4.34, m 
-COCH3 
1.98, s 
2.01, s 
2.04-2.10, m 
1.87, s 
2.00, s 
2.02, s 
2.04-2.07, m 
1.88, s 
1.98-2.10, m 
 
1.87, s 
2.00, s 
2.02, s 
2.04-2.07, m 
[a] Compound 5d is a mixture of cis and trans isomers. In this table, only the proton signals 
correspondent to the trans isomer are considered since it is the most abundant isomer. The 1H 
NMR data may be consulted in the sub-chapter 5.2.3. [b] Protons H-α and H-β are 
indistinguishable in this case. 
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Figure 2.8 – 13C NMR spectrum (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-4-(4-
chlorostyryl)-3-(2-hydroxyphenyl)-1H-pyrazole (5b) [(CD3)2CO, 75.47 MHz]. 
 
1D and 2D NMR experiments allowed the assignment of the proton and carbon 
resonances of compounds 5a-d and revealed the nature of the formed glycosidic bond. 
Theoretically, both O-glycosylated and N-glycosylated products could have been obtained 
from the glycosylation reaction performed in this work (review sub-chapter 2.2.3.). Since 
compounds 5a-d present the resonance of the 2’-OH proton in the 1H NMR (at  9.53 – 
9.74 ppm, see Table 2.2), it’s possible to infer that compounds 5a-d are N-glycosylated. 
Also, the presence of the resonance of 2’-OH proton at  9.53 – 9.74 ppm is indicative of a 
hydrogen bond between the 2’-OH and the N2 of the pyrazole nucleus. This non-covalent 
bond may cause hindrance to O-glycosylation. The NOESY correlations observed for 
compound 5b (Scheme 2.8) are used to exemplify N-glycosylation in this class of 
compounds. Indeed, the NOESY spectrum of compound 5b shows a correlation between 
2’-OH → H-3’ and H-2’’’. In the case of O-glycosylation, the 2’-OH proton would have 
been removed and the mentioned correlations would not be observed, that is the presence 
of these correlations is intrinsic evidence that compound 5b is N-glycosylated. This 
conclusion is further supported by the correlations H-5 → H-1’’’ and H-2’’’. The 
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correlation found in the HMBC spectrum of compound 5b (H-1’’’→ C-5), also proves the 
linkage of the sugar moiety to the N1 position of the pyrazole ring. Since all compounds 5 
present the resonance of the 2’-OH proton in the 1H NMR ( 9.53 – 9.74 ppm, see Table 
2.2), it’s possible to confirm that compounds 5a-d are N-glycosylated.  
 
Scheme 2.8 – Main correlations (blue arrows) observed in the NOESY spectra of compound 5b.  
2.3.3.  1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-
5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-styryl-1H-
pyrazoles 
The structure of the novel compounds 6a-d was determined based on 1D (1H and 
13C) and 2D (HSQC, HMBC and NOESY) NMR experiments. The most characteristic 
signals in the 1H NMR spectra of compounds 6 are due to the sugar moiety (as example see 
the 1H NMR spectrum of 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-4-(4-chlorostyryl)-3-(2-
hydroxyphenyl)-1H-pyrazole (6b) in the Figure 2.9). Typically, the 1H NMR spectra of 
compounds 6a-d presents a doublet due to the resonance of proton H-3a’’’ at  5.75 – 6.18 
ppm and two doublet of doublets of doublets corresponding to H-6’’’ ( 4.89 – 4.99 ppm) 
and H-5’’’ ( 4.42 – 4.47 ppm) proton resonances (see Table 2.3). A triplet corresponding 
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to the H-7’’’ resonance is usually detected at  5.14 – 5.26 ppm with a coupling constant 
around J = 2.3 – 2.9 Hz. There’s also a multiplet due to the resonance of 5’’’-CH2OCOCH3 
at  4.24 – 4.33 ppm and a triplet corresponding to the proton H-7a’’’ at  4.21 – 4.24 ppm. 
Also, the highly shielded proton resonance due to 2’’’-CH3 ( 2.19 ppm) is an evidence 
that confirms the structure proposed for compounds 6a-d. The remaining typical signals 
are due to the resonance of -COCH3 protons. In most cases there is a multiplet at  2.05 – 
2.10 ppm due to the resonance of two -COCH3 groups and one broad singlet at  2.13 ppm 
due to the resonance of three protons of one -COCH3 group. Notice that compounds 6a-d 
only present three protecting groups when compared to compounds 5a-d (compare Figure 
2.7 and 2.9).   
 
 
Figure 2.9 – 1H NMR spectrum of 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)- 
1H-pyrazole (6b) [(CD3)2CO, 300.13 MHz]. An expansion of the aliphatic region, from  2.0  – 
2.3 ppm, was presented to facilitate the analysis of the spectrum.  
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Table 2.3 – Chemical shifts (ppm, relative to TMS) and coupling constants (J, Hz) of 1H NMR of 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 6a-d.  
              Compound          
                     
Signal 
6a 6b 6c 6d[a] 
H-5 8.37, s 8.38, s 8.43, s 8.16, s 
2’-OH 10.12, s 10.08, s − 9.74, s 
H-3’ 
7.02, dd 
J 7.8, 1.1 
7.02, dd 
J 8.0, 1.1 
7.02, dd 
J 8.2, 1.2 
6.93-7.01, m 
H-4’ 7.27-7.32, m 
7.29, ddd 
J 8.0, 7.6, 1.6 
7.28-7.34, m 
7.25, ddd 
J 8.2, 7.7, 1.5 
H-5’ 6.96-6.98, m 
6.97, ddd 
J 7.7, 7.6, 1.1 
6.96, dt 
J 7.6, 1.2 
6.93-7.01, m 
H-6’ 
7.67, dd 
J 7.8, 1.6 
7.65, dd 
J 7.7, 1.6 
7.61, dd 
J 7.6, 1.6 
7.69, d 
J 7.5 
H-2’’ 
7.55, d 
J 7.4 
7.56, d 
J 8.6 
− 
7.50, d 
J 8.7 
H-3’’ 
7.38, t 
J 7.4 
7.39, d 
J 8.6 
7.75, d 
J 7.8 
6.95, d 
J 8.7 
H-4’’ 7.27-7.32, m − 
7.50, t 
J 7.8 
− 
H-5’’ 
7.38, t 
J 7.4 
7.39, d 
J 8.6 
7.68, t 
J 7.8 
6.95, d 
J 8.7 
H-6’’ 
7.55, d 
J 7.4 
7.56, d 
J 8.6 
7.93, d 
J 7.8 
7.50, d 
J 8.7 
H-α 
7.24, d 
J 16.5 
7.26, d 
J 16.2 
7.26, d 
J 16.0 
7.15, d[b] 
J 16.2 
H-β 
7.07, d 
J 16.5 
7.05, d 
J 16.2 
7.28-7.34, m 
6.96, d[b] 
J 16.2 
2’’’-CH3 2.19, s 2.19, s 2.19, s −[c] 
H-3a’’’ 
6.18, d 
J 5.2 
6.17, d 
J 5.2 
6.16, d 
J 5.2 
5.75, d 
J 5.4  
H-5’’’ 
4.46, ddd 
J 5.2, 2.8, 0.9 
4.46, ddd 
J 5.2, 2.8, 0.9 
4.47, ddd 
J 5.2, 2.3, 0.8 
4.42, ddd 
J 5.4, 3.1, 0.8 
H-6’’’ 
4.97, ddd 
J 9.1, 1.8, 0.9 
4.99, ddd 
J 9.8, 2.0, 0.9  
4.98, ddd 
J 8.5, 2.0, 0.8 
4.89, ddd 
J 9.6, 3.1, 0.8 
H-7’’’ 
5.25, t 
J 2.8 
5.26, t 
J 2.8 
5.25, t 
J 2.3 
5.14, t 
J 2.9 
H-7a’’’ 
4.23, t 
J 5.2 
4.24, t 
J 5.2 
4.21, t 
J 5.2 
−[c] 
5’’’-CH2OCOCH3 4.26-4.31, m 4.25-4.33, m 4.25-4.31, m 4.24-4.31, m 
-COCH3 
2.05-2.10, m 
2.13, br s 
2.05-2.07, m 
2.13, br s 
2.05-2.07, m 
2.13, br s 
−[c] 
[a] Compound 6d is a mixture of cis and trans isomers. This table only contemplates the proton 
signals correspondent to the trans isomer. The full 1H NMR data may be consulted in the sub-
chapter 5.2.3. [b] Protons H-α and H-β are indistinguishable in the 1H NMR spectrum. [c] It was 
not possible to identify the signals due to the resonance of these protons.  
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Regarding the 13C NMR spectra of compounds 6a-d, the most characteristic signals 
are due to the carbon resonances of the sugar moiety [as example see the 13C NMR 
spectrum of 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-4-(4-chlorostyryl)-3-(2-
hydroxyphenyl)-1H-pyrazole (6b) (Figure 2.10)].  
 
 
Figure 2.10 – 13C NMR spectrum of 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)- 
1H-pyrazole (6b) [(CD3)2CO, 75.47 MHz].  
 
The most relevant carbon resonances corresponding to the sugar moiety are: C-
3a’’’ ( 98.9 ppm), C-5’’’ ( 73.8 ppm), C-7’’’ ( 70.1 ppm), C-6’’’ ( 68.8 ppm), C-7a’’’ 
( 68.4 ppm), and 5’’’-CH2OCOCH3 ( 63.8 – 63.9 ppm). Notice that most of these carbon 
resonances appear at the same chemical shift for all derivatives 6a-d. The resonance of C-
3a’’’ appears at high frequency values since it is bounded to two oxygen atoms. 
Additionally, in the 13C NMR spectra of compounds 6 is also usual to observe the 
resonances of C-2’’’ and 2’’’-CH3 at  114.5 – 114.6 ppm and  24.3 – 24.4 ppm, 
respectively. Finally, concerning the resonance of the carbons of the acetyl protecting 
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groups, they usually appear at  169.5 – 170.8 ppm for -COCH3 and at  20.6 – 20.8 ppm 
for -COCH3. 
The 1D and 2D NMR data also demonstrated that compounds 6 are N-glycosylated. 
The NOESY correlations which reinforced the nature of the glycosidic bound will be 
presented in the Scheme 2.9, taking compound 6b as example. The following correlations 
2’-OH → H-3’ and H-3a’’’ unequivocally prove the nature of the glycosidic bound. The N-
glycosylation is also supported by the correlation H-5 → H-3a’’’ and H-7’’’. Nevertheless, 
the presence in the 1H NMR spectra of the signal due to the resonance of 2’-OH is enough 
to prove that the O-glycosylation didn’t occur. The signal due to the resonance of 2’-OH is 
present in all compounds 6 at  9.74 – 10.12 ppm, see Table 2.3, except for compound 6c. 
Still, in the NOESY spectrum of compound 6c (not shown) it’s possible to see the 
correlation H-5 → H-3a’’’, which ensures that compound 6c is N-glycosylated at N1 
position of the pyrazole moiety. Once again, the chemical shifts of the 2’-OH proton ( 
9.74 – 10.12 ppm) indicate the presence of a hydrogen bond between the 2’-OH and the N2 
atom. Since all the compounds obtained in the glycosylation of the pyrazoles 4a-d were N-
glycosylated, we may infer that probably due to the steric hindrance and to the existence of 
an intramolecular hydrogen bond between 2’-OH and N2 the O-glycosylation is more 
difficult to occur than the N-glycosylation. The stereochemistry of H-3a”’ and H-7a”’ was 
attributed based on the correlation observed in the NOESY spectra H-3a”’H-7a”’, thus 
indicating a cis configuration of these two protons.  
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Scheme 2.9 – Main correlations (blue arrows) observed in the NOESY spectra of compound 6b.  
2.3.4.  (E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 
The structure of compounds 7 was established based on 1D (1H and 13C) and 2D 
(HSQC, HMBC, COSY and NOESY) NMR experiments. The compounds result from 
cleavage of the acetyl protecting groups of compounds 5a-d, and for this the main 
difference in the 1H NMR spectra of compounds 7 is the absence in the aliphatic region of 
the spectra of the signals ascribed to the protons of the protecting groups of the sugar 
moiety. As example, the 1H NMR spectrum of (E)-4-(4-chlorostyryl)-1-[β-D-(glycose-1-
yl)]-3-(2-hydroxyphenyl)-1H-pyrazole (7b) is given in the Figure 2.11. Also noteworthy is 
the presence of two doublet of doublets due to the resonance of 6’’’-CH2OH protons. The 
resonance of one of these protons appears at  3.72 – 3.73 ppm with J = 11.9 – 12.0, 4.8 – 
5.3 Hz and the resonance due to the other proton appears at  3.89 ppm with J = 11.9 – 
12.0, 1.8 – 2.2 Hz, except for compound 7d, as seen in the Table 2.4. Since C-5’’’ is a 
chiral center, 6’’’-CH2OH protons are diastereotopic with different chemical environment 
and they give separate signals. The typical signals of compounds 5 and 7 may be the same, 
but their chemical shift is not. The signals due to the resonance of the protons of sugar 
moiety of compounds 7, are observed in their 1H NMR spectra in the following descending 
order (from the highest to the lowest chemical shift): H-1’’’ ( 5.28 – 5.47 ppm), H-2’’’ ( 
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3.91 – 4.09 ppm), 6’’’-CH2OH protons (as already mentioned), H-3’’’ ( 3.63 – 3.69 ppm), 
H-5’’’ ( 3.47 – 3.63 ppm) and H-4’’’ ( 3.42 – 3.58 ppm). 
 
Figure 2.11 – 1H NMR spectrum of (E)-4-(4-chlorostyryl)-1-[β-D-(glycose-1-yl)]-3-(2-
hydroxyphenyl)-1H-pyrazole (7b) [(CD3)2CO, 500.16 MHz] and expansion showing the signals of 
the sugar moiety at  3.5 – 4.1 ppm.  
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Table 2.4 – Chemical shifts (ppm, relative to TMS) and coupling constants (J, Hz) of 1H NMR of 
(E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 7a-d.  
        Compound                       
 
Signal 
7a 7b 7c 7d[a] 
H-5 8.35, s 8.37, s 8.45, s 8.15, s 
2’-OH − − − − 
H-3’ 
7.00, dd 
J 8.4 
7.00, dd 
J 7.8, 1.0 
7.01, dd 
J 8.0, 1.0 
6.82-6.86, m 
H-4’ 7.25-7.29, m 7.26-7.30, m 
7.28, dt 
J 8.0, 7.6, 1.7 
7.12, dt 
J 7.8, 1.6 
H-5’ 
6.98, t 
J 7.6 
6.97, ddd 
J 7.8, 7.5, 1.0 
6.97, dt 
J 7.6, 1.0 
6.82-6.86, m 
H-6’ 
7.68, dd 
J 7.6, 1.2 
7.67, dd 
J 7.8, 1.5 
7.65, dd 
J 7.6, 1.7 
7.54, dd 
J 7.8, 1.6 
H-2’’ 
7.56, d 
J 7.6 
7.59, d 
J 8.5 
− 
7.36, d 
J 8.7  
H-3’’ 
7.38, t 
J 7.6 
7.40, d 
J 8.5 
7.75, d 
J 7.8 
6.81, d 
J 8.7 
H-4’’ 7.25-7.29, m − 
7.50, t 
J 7.8 
− 
H-5’’ 
7.38, t 
J 7.6 
7.40, d 
J 8.5 
7.68, t 
J 7.8 
6.81, d 
J 8.7 
H-6’’ 
7.56, d 
J 7.6 
7.59, d 
J 8.5 
7.97, d 
J 7.8 
7.36, d 
J 8.7 
H-α 7.25-7.29, m 
7.29, d 
J 16.3 
7.30-7.33, m 
6.98, d 
J 16.4[b] 
H-β 
7.07, d 
J 16.2 
7.07, d 
J 16.3 
7.30-7.33, m 
6.86, d 
J 16.4[b] 
H-1’’’ 
5.44, d 
J 9.3 
5.44, d 
J 9.1 
5.47, d 
J 9.1 
5.28, d  
J 8.9 
H-2’’’ 
4.07, t 
J 9.3 
4.06, t 
J 9.1 
4.09, t 
J 9.1 
3.91, t 
J 8.9 
H-3’’’ 
3.67, t 
J 9.3 
3.67, t 
J 9.1 
3.66, t 
J 9.1 
3.63-3.69, m 
H-4’’’ 
3.58, t 
J 9.3 
3.57, t 
J 9.1 
3.56, t 
J 9.1 
3.42, t 
J 8.9 
H-5’’’ 
3.63, ddd 
J 9.3, 4.8, 1.8 
3.63, ddd 
J 9.1, 5.3, 2.2 
3.62, ddd 
J 9.1, 5.3, 2.0 
3.47-3.61, m 
6’’’-CH2OH 
3.73, dd 
J 11.9, 4.8 
3.72, dd 
J 12.0, 5.3 
3.72, dd 
J 12.0, 5.3 
3.69-3.79, m 
6’’’-CH2OH 
3.89, dd 
J 11.9, 1.8 
3.89, dd 
J 12.0, 2.2 
3.89, dd 
J 12.0, 2.0 
3.69-3.79, m 
Compound 7d is a mixture of cis and trans isomers. This table only presents the proton signals 
correspondent to the trans isomer. The full 1H NMR data may be consulted in the sub-chapter 
5.2.3. [b] Protons H-α and H-β are indistinguishable in the 1H NMR spectrum. 
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The 13C NMR spectra of compounds 7a-d also confirms the removal of the 
protecting groups as no signals of these carbons are present. The example spectrum of 
compound 7b is presented in the Figure 2.12. Besides this feature, there are no other 
significant changes in the 13C NMR spectra. The 6’’’-CH2OH protons were assigned as 
diastereotopic through the HSQC correlations. The two distinct proton resonances 
corresponding to 6’’’-CH2OH protons were both correlated to the C-6’’’ in the HSQC 
spectrum, which allowed their unequivocal identification.  
 
 
Figure 2.12 – 13C NMR spectrum of (E)-4-(4-chlorostyryl)-1-[β-D-(glycose-1-yl)]-3-(2-
hydroxyphenyl)-1H-pyrazole (7b) [(CD3)2CO, 75.47 MHz].  
 
2.3.5.  1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-hydroxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-
4-styryl-1H-pyrazoles 
The structure of compounds 8a,b was determined based on 1D (1H and 13C) and 2D 
(HMBC, HSQC and NOESY) NMR experiments. Compounds 8a,b were obtained from 
compound 6a and compound 6c by cleavage of the acetyl protecting groups. Thus the main 
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characteristic in the 1H NMR spectra of compounds 8a,b is the absence of the signals due 
to the resonance of the protons of the acetyl protecting groups, in the aliphatic region of the 
spectra (see as example, the spectrum of (E)-4-(4-chlorostyryl)-1-[(2R,3aR,5R,6S,7S,7aR)-
6,7-dihydroxy-5-hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-3-
(2-hydroxyphenyl)-1H-pyrazole (8b) in the Figure 2.13).  
 
Figure 2.13 – 1H NMR spectrum of (E)-4-(4-chlorostyryl)-1-[(2R,3aR,5R,6S,7S,7aR)-6,7-
dihydroxy-5-hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-3-(2-
hydroxyphenyl)-1H-pyrazole (8b) [(CD3)2CO, 500.16 MHz].  
Regarding the other signals there are some changes when compared to compounds 
6a-d. The signals due to the resonance of protons of the sugar appear at different chemical 
shifts when comparing compounds 6a-d and 8a,b (see Table 2.5). In the case of 
compounds 8a-d the signals appear in the following order (from the highest to the lowest 
chemical shift): H-3a’’’ ( 5.97 – 5.98 ppm), H-7a’’’ ( 4.30 – 4.31 ppm), H-7’’’ ( 4.03 
ppm), H-5’’’ ( 3.73 – 3.78 ppm), 5’’’-CH2OH ( 3.86 ppm), 5’’’-CH2OH ( 3.73 – 3.78 
ppm) and H-6’’’ ( 3.66 ppm), as seen in the Table 2.5. Notice that protons 5’’’-CH2OH 
are diastereotopic and therefore appear at different chemical shifts. 
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Table 2.5 – Chemical shifts (ppm, relative to TMS) and coupling constants (J, Hz) of 1H NMR of 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-hydroxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 8a,b.  
                  Compound 
 
Signal 
8a 8b 
H-5 8.38, s 8.43, s 
2’-OH 10.25, br s – 
H-3’ 
7.01, d 
J 8.3 
7.02, dd 
J 8.2, 1.1 
H-4’ 7.27-7.30, m 7.27-7.37, m 
H-5’ 
6.97, t 
J 7.6 
6.96, ddd 
J 7.5, 7.7, 1.1 
H-6’ 
7.67, dd 
J 7.6, 1.1 
7.64, dd 
J 7.7, 1.6 
H-2’’ 
7.58, d 
J 8.5 
– 
H-3’’ 
7.40, d 
J 8.5 
7.75, d 
J 7.8 
H-4’’ – 
7.50, t 
J 7.8 
H-5’’ 
7.40, d 
J 8.5 
7.68, t 
J 7.8 
H-6’’ 
7.58, d 
J 8.5 
7.95, d 
J 7.8 
H-α 
7.29, d 
J 16.1 
7.31, d 
J 16.0 
H-β 
7.10, d 
J 16.1 
7.30, d 
J 16.0 
2’’’-CH3 2.19, s 2.13, s 
H-3a’’’ 
5.98, d 
J 4.6 
5.97, d 
J 4.8 
H-5’’’ 3.73-3.78, m 
3.78, dd 
J 5.6, 2.3 
H-6’’’ 
3.66, dd 
J 8.5, 3.9  
3.66, dd 
J 8.9, 4.4 
H-7’’’ 
4.03, t 
J 3.9 
4.03, t 
J 4.4 
H-7a’’’ 
4.30, t 
J 4.6 
4.31, t 
4.8 Hz 
5’’’-CH2OH 
3.86, d, 
J 10.0 
3.86, dd 
J 11.2, 2.3 
5’’’-CH2OH 
3.73-3.78, m 
 
3.73, t 
J 5.6 
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The 13C NMR data confirms the removal of the protecting groups. As example, see 
the spectrum of (E)-4-(4-chlorostyryl)-1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-
hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-3-(2-
hydroxyphenyl)-1H-pyrazole  (8b) in the Figure 2.14. Additionally, it’s possible to 
perceive that the signals due to the carbon resonances of the sugar moiety are different 
when compared to compounds 6a-d. These signals appear in the spectra of compounds 
8a,b from the highest to the lowest chemical shift as: C-3a’’’ ( 99.5 – 99.6 ppm), C-7a’’’ 
( 78.2 –  78.3 ppm), C-5’’’ ( 74.9 ppm), C-7’’’ ( 73.7 – 73.8 ppm), C-6’’’ ( 70.4 ppm) 
and 5’’’-CH2OH ( 63.0 ppm). There are no other significant changes in the 13C NMR 
spectra of compounds 8a,b when compared to those of compounds 6a-d. 
 
 
Figure 2.14 – 13C NMR spectrum of (E)-4-(4-chlorostyryl)-1-[(2R,3aR,5R,6S,7S,7aR)-6,7-
dihydroxy-5-hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-3-(2-
hydroxyphenyl)-1H-pyrazole (8b) [(CD3)2CO, 75.47 MHz]. 
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Chapter 3 
 
 
  Synthesis of ruthenium complexes with pyrazoles  
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3.1.  Nomenclature adopted for the ruthenium-pyrazole complexes 
The nomenclature adopted for the novel complexes [Ru([9]aneS3)((E)-3(5)-(2-
hydroxyphenyl)-4-(2-/4-Rstyryl)-1H-pyrazole)(DMSO)Cl]Cl does not follow the IUPAC 
rules. The structure of these compounds and the respective carbon numbering system may 
be consulted in the Figure 3.1. The nomenclature and numbering system for the pyrazole 
scaffold follows the rationale described in the sub-chapter 2.1.2. 
 
Figure 3.1 – Structure and atom numbering for the complexes with the general formula 
[Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-(2-/4-R-styryl)-1H-pyrazole)(DMSO)Cl]Cl. The 
stereochemistry presented here is merely representative. 
 
3.2.  Preparation of the complexes 
The complexes were obtained by adapting the procedure of Marques et al (see 
Scheme 3.1).20 Briefly, the precursor Ru([9]anesS3)(DMSO)Cl2 is allowed to react with the 
compounds 4a-4d in refluxing methanol, under  a nitrogen atmosphere, for 18h.  
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Scheme 3.1 – Complexation of the free pyrazole derivatives 4a-d with Ru([9]anesS3)(DMSO)Cl2. 
The prototropy effect in 4a-d is also depicted. The stereochemistry presented here is merely 
representative. 
 
3.3.  Structural characterization of the ruthenium-pyrazole complexes 
The structural characterization of the family of complexes 9 was performed by 
NMR, namely 1D (1H and 13C) and 2D (HMBC, HSQC and NOESY) techniques, infrared, 
mass spectrometry and elemental analysis. Typically, the spectra of the complexes present 
a set of signals ascribed to the resonance of the protons of the macrocycle, [9]aneS3, as 
well as those of the corresponding pyrazole ligand and of DMSO, that remained in the 
coordination sphere. As an example, the spectrum of the complex [Ru([9]aneS3)((E)-4-(4-
chlorostyryl)-3(5)-(2-hydroxyphenyl)-1H-pyrazole)(DMSO)Cl]Cl (9b) is presented in the 
Figure 3.2. Some protons present two signals, indicating the presence of non-equivalent 
stereochemistry around the ruthenium coordination sphere. This is observed for the signals 
corresponding of the NH, 2’-OH and H-5 protons. Note also that the intensities of the 
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mentioned signals are different, indicating that one of the species is predominant over the 
other. The NH, 2’-OH and H-5 signals at  12.90 – 13.09, 10.80 – 10.90 and 8.26 – 8.30 
ppm, respectively, are attributed to the most abundant ruthenium complex (see Table 3.1). 
Therefore, the NH, 2’-OH, H-5 resonance signals at  12.85 – 13.10, 10.58 – 10.65 and 
8.24 – 8.34 ppm, respectively, are attributed to the less abundant ruthenium complex. 
Herein only the signals of the most abundant species will be presented, for simplicity of the 
discussion. The remaining data and its attribution can be consulted in the sub-chapter 5.2.5. 
For the protons of the pyrazole ligand, it is possible to determine a coupling 
constant between H-α and H-β ranging between J = 15.8 – 16.3 Hz, thus indicating that the 
vinylic system retained the trans configuration. Regarding the typical resonance signals of 
the [9]aneS3 macrocycle, they appear as a multiplet at  2.57 – 2.88 ppm. The integration 
of the 1H NMR signals of [9]aneS3 tallies well with the expected 12 protons. Next to the 
[9]aneS3 resonances there is a multiplet at  2.88 – 3.14 ppm corresponding to six DMSO 
proton resonances. 
 
 
Figure 3.2 – 1H NMR spectrum of [Ru([9]aneS3)((E)-4-(4-chlorostyryl)-3(5)-(2-hydroxyphenyl)-
1H-pyrazole)(DMSO)Cl]Cl (9b) (DMSO-D6, 500.16 MHz).  
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Table 3.1 – Chemical shifts (ppm, relative to TMS) and coupling constants (J, Hz) of 1H NMR of 
[Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazole)(DMSO)Cl]Cl 9a-d. Only the 
most abundant signals are presented here.  
        Compound          
 
Signal 
9a 9b 9c 9d 
NH 12.93, s 12.95, s 13.09, s 12.90, s 
2’-OH 10.90, s 10.90, s 10.80, s 10.90, s 
H-5 
8.29, d 
J 2.0 
8.30, d 
J 1.9 
8.30, d 
J 1.9 
8.26, d 
J 1.9 
H-3’ 7.07-7.08, m 7.04-7.11, m 7.06-7.07, m 
7.06, d 
J 7.9 
H-4’ 7.19-7.31, m 7.26-7.41, m 7.30-7.36, m 
7.32, ddd 
J 7.9, 7.8, 1.3 
H-5’ 7.00-7.05, m 
7.01, t 
J 7.6 
6.98, t  
J 7.5 
6.99-7.05, m 
H-6’ 
7.52, dd 
J 7.8, 1.6 
7.51, dd 
J 7.6, 1.4 
7.46, d 
J 7.5 
7.53, dd 
J 7.8, 1.3 
H-2’’ 
7.55, d 
J 7.6 
7.57, d 
J 8.5 
− 
7.49, d 
J 8.8 
H-3’’ 
7.38, t 
J 7.6 
7.43, d 
J 8.5 
7.73, d 
J 7.7 
6.95, d 
J 8.8 
H-4’’ 7.19-7.31, m − 
7.49, t 
J 7.7 
− 
H-5’’ 
7.38, t 
J 7.6 
7.43, d 
J 8.5 
7.67, t 
J 7.7 
6.95, d 
J 8.8 
H-6’’ 
7.55, d 
J 7.6 
7.58, d 
J 8.5 
7.89, d 
J 7.7 
7.49, d 
J 8.8 
H-α 
7.03, d 
J 16.2 
7.08, d 
J 16.2 
7.10, d 
J 15.8 
6.84, d 
J 16.3 
H-β 
7.10, d 
J 16.2 
7.23, d 
J 16.2 
7.03, d 
J 15.8 
7.17, d 
J 16.3 
Ru[9]aneS3 2.57-2.85, m 2.59-2.88, m 2.59-2.86, m 2.59-2.87, m 
Ru-DMSO 2.95-3.06, m 2.91-3.10, m 2.88-3.04, m 2.95-3.14, m 
 
 
The 13C NMR spectra of the complexes also presents resonances in two well 
defined regions:   30.1 – 35.2 ppm for the [9]aneS3 carbon resonances and  114.0 – 
158.9 ppm for the pyrazole ligand resonances. An example is the spectrum of complex 9b 
depicted in the Figure 3.3. Some carbon atoms also give rise to two signals (same as 
observed for the proton resonances), which is attributed to the presence of two non-
equivalent geometries.  
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Figure 3.3 – 13C NMR spectrum (DMSO-D6, 500.16 MHz) of [Ru([9]aneS3)((E)-4-(4-
chlorostyryl)-3(5)-(2-hydroxyphenyl)-1H-pyrazole)(DMSO)Cl]Cl (9b).  
 
The NOESY correlation 2’-OH → NH allows inferring the N-coordination of 
compounds 4 to the ruthenium centre. This correlation implies that the ligand coordination 
occurred at the N1 of the pyrazole ring (as depicted in Scheme 3.1). Had the coordination 
taken place at the adjacent N, this correlation would not be visible, because, to avoid steric 
hindrance, the phenol ring would rotate to have the 2’-OH away from the pyrazole and thus 
it would not be able to correlate with NH. This correlation is also indicative of the 
coordination of compounds 4a-d to the ruthenium centre in a monodentate fashion at the 
N1 of the pyrazole moiety.  
3.4.  Mass spectrometry of the ruthenium-pyrazole complexes 
The mass spectrometry results corroborate the theoretically predictions. Recall that 
these complexes are already positively charged, so the most intense peak in the mass 
spectrometry spectra is supposed to match the value of their theoretical exact mass. The 
ESI-MS data of compound 9a shows the molecular cation as the most intense peak, at 
657.1 m/z, which tallies well with the theoretical mass of 657. Regarding compound 9b, 
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two intense peaks are present in its mass spectrometry spectrum. Since this compound has 
a chlorine atom, the two isotopes 35Cl and 37Cl may occur. The base peak at 693.0 m/z 
corresponds to the complex 9b with the isotope 37Cl and the peak with a slightly lower 
intensity at 691.0 m/z corresponds to the complex 9b with the isotope 35Cl. These results 
are in agreement with the theoretical exact mass of complex 9b of 691.0. For complex 9c, 
there is a base peak at 725.0 m/z, which matches with its exact mass of 725.0. Finally, 
complex 9d mass spectrometry spectrum has a base peak at 687.1 m/z, which matches its 
exact mass of 687.1. The mass spectrometry analysis also allowed to confirm that the 
ruthenium coordination occurred by replacement of one chloride rather than the DMSO. 
3.5.  Fourier-transform infrared of the ruthenium-pyrazole complexes 
 
 The attribution of the bands associated with the pyrazole ligands was made with 
base on the report by Krishnakumar et al97 (details in sub-chapter 5.2.2). The 
ωCCvibration, occurring at 960 – 966 cm-1 in compounds 4a-d, appear in the 965 – 
967 cm-1 region in the spectra of complexes 9a-d, that is, this band is practically unshifted 
and it further indicates that the trans configuration of the vinylic system98 was not altered 
upon coordination. The νC=C stretching bands of the aromatic groups of the ligand, 
including pyrazole and aryl groups, are somewhat overlapped; nevertheless, a band at 1605 
– 1639 cm-1 corresponding to the νC=N vibration allows to confirm the presence of this 
ligand in the complexes. The spectra of the complexes 9a-d also present, as expected, 
several vibrations associated with the macrocycle, such as the νC–H vibration at 2961 – 
2966 (except for complex 9c), the νC–H vibration at 2921 – 2926 and the ρC–H vibration 
at 908 – 910 cm-1. The infrared spectra of complexes 9a-d also present bands 
corresponding to the ρC–H(DMSO) vibrations at 908 – 910 cm-1 and 822 – 829 cm-1. 
Complexes 9b and 9d infrared spectrum also present the νRu–S(macrocycle) vibration at 455 – 
457 cm-1. This vibration is also verified for complexes 9a and 9d at 493 cm
-1. Notice that 
complex 9c didn’t display any bands corresponding to the Ru–S(macrocycle) vibration. 
Complexes 9a-d display the νRu–S(DMSO) vibration at 424 – 425 cm-1 which in parallel 
with the ρC–H(DMSO) vibrations reassure the presence of DMSO in the ruthenium sphere. 
At last, the νRu–N stretching band is observed in the 373 – 377 cm-1 region, thus 
confirming the Ru coordination. 
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Chapter 4 
 
   Biological assays  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
The compounds 4a-d, 7a-c, 8a,b and complexes 9a-d were tested against the AGS 
cancer cell line. Compounds 4a-d, 7b,c, 8a,b and 9d were tested against the MRC-5 cell 
line. The results are discussed below. For experimental details refer to the sub-chapter 
5.2.6. 
4.1.1. AGS cancer cell line 
The concentrations of the tested compounds were adjusted according to their 
activity. The compounds were initially tested at concentrations of 1:4 (0.39, 1.56, 6.25, 25 
and 100 μM), however, in some cases these concentrations were not the most indicated to 
the IC50 calculation. Throughout this work it was clear that concentrations of 1:2 (6.25, 
12.5, 25, 50 and 100 μM) fitted better the cytotoxic activity results of the tested 
compounds since they often presented IC50 values around 50 – 100 μM. Consequently, 
there are compounds tested in the 0.39 – 100 μM range and others tested in the 6.25 – 100 
μM range. The attained cell viability results may be consulted in the Figure 4.1 and the 
general structure of the tested compounds and their corresponding IC50 values may be 
consulted in the Table 4.1. 
 Concerning compounds 4a-d, the -para-Cl substituted compound 4b is the only 
one to present a measurable IC50 under 100 μM, with an IC50 of 37 μM. Yet, even though 
the -ortho-CF3 substituted compound 4c has IC50 > 100 μM, it was more active than the 
non-substituted compound 4a and the -para-OCH3 substituted compound 4d. Compounds 
4a and 4d revealed to be inefficient against the AGS cancer cell line.   
  For compounds 7a-c it’s not possible to discuss the electron-donating group effect 
since these compounds are either non-substituted (7a), halogen substituted (7b) or 
substituted with an electron-withdrawing group in the phenyl ring (7c). The non-
substitution of the phenyl ring had no benefit in the cytotoxic activity. In fact, at the 
concentration of 25 μM, compound 7a appears to promote AGS cancer cells’ metabolism. 
To inspect whether compound 7a triggers cancer cells metabolism or proliferation at this 
concentration, in the future it is advisable to perform a Sulforhodamine B assay.99 
Regarding compounds 7b and 7c, their IC50 is quite similar (78.8 and 73.0 μM, 
respectively). Notice that the insertion of the R3 = Glc improved compound’s 7c IC50 when 
compared to its precursor, compound 4c. However, the IC50 of 7b is worse than its 
precursor, compound 4b. Further studies should be conducted to understand if the insertion 
65 
 
of the R3 = Glc group is a good strategy for the enhancement of the in vitro cytotoxic 
activity. 
Regarding compounds 8a,b, compound 8a afforded a poorer IC50 (74.2 μM) than 
its precursor, compound 4b. Since compounds 7b and 8a revealed to be less potent than 
compound 4b, the insertion of a glucose unit in the -para-Cl substituted compound 4b 
doesn’t seem to be beneficial for its cytotoxic activity. Still, the -ortho-CF3 substituted 
compound 8b disclosed an IC50 value of 41.3 μM and thus, it was more potent than its 
precursor, 4c, which didn’t present a measurable IC50 below 100 μM. Also, compound 8b 
IC50 value was better than the other -ortho-CF3 substituted compound, 7c. So, in the case of 
-ortho-CF3 substituted compounds, the insertion of R
3 = Dx is better than the insertion of 
R3 = Glc. Altogether, it’s possible to verify that the insertion a sugar moiety (R3 = Dx or 
Glc) improves the cytotoxic activity of the -ortho-CF3 substituted compounds 7c and 8b, 
when compared to 4c, and jeopardizes the cytotoxic activity of the -para-Cl substituted 
compounds 7b and 8a when compared to 4b.  Due to these results, with would be 
interesting to study the cytotoxic activity of -para-CF3 and -ortho-Cl substituted 
compounds. 
The ruthenium complexes, 9a-d comprise the most potent compound in the present 
study. Even though the non-substituted (9a), the halogen substituted (9b) and the electron-
withdrawing substituted (9c) compounds did not afford cytotoxic activity below 100 μM, 
the -para-OCH3 substituted compound (9d) presented an IC50 value of 18.3 μM. Note that 
the literature describes good inhibitory action for another ruthenium trithiacyclononane 
complex with a parent ligand, 3-(2-hydroxy)-phenyl-5-R-styryl pyrazole, in which the R-
substituent was precisely a methoxyl group in the -para position of the aromatic ring of 
styryl.20 This suggests that, when coordinated with Ru([9]aneS3), disubstituted pyrazoles 
bearing -para-OCH3 groups promote a better cytotoxic activity in vitro. In the future it 
would be pertinent to study the effect of other electron-donating groups in the cytotoxic 
activity of Ru [9]aneS3 complexes with disubstituted pyrazoles of the same family.  
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Figure 4.1 – Cytotoxic effect of compounds 4a-d, 7a-c, 8a,b and 9a-d against the AGS cancer cell 
line. The cells were incubated with five different concentrations of these compounds for 24h. The 
data is expressed as % of viability and represents the mean ± mean standard deviation from three to 
four independent experiments run in triplicate. * denotes p-value < 0.05, ** denotes p-value < 0.01, 
*** denotes p-value < 0.001 and **** denotes p-value < 0.0001. 
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4.1.2.  MRC-5 cell line 
 Due to the slow proliferation rate of the MRC-5 cell line, it wasn’t possible to test 
all the compounds against this cell line (see Figure 4.2). 
Compounds 4a-d afforded measurable IC50 values under 100 μM when tested 
against the MRC-5 cell line (see Table 4.1). With exception of compound 4b, this set of 
compounds showed higher cytotoxicity against the MRC-5 than AGS cell line. Even 
though compound 4b presented a better cytotoxic action against the AGS cell line than 
Table 4.1 – Structural representation and cytotoxic activity of compounds 4a-d, 7a-c, 8a,b and 9a-
d against the AGS cancer cell line. The results are expressed as IC50 (μM). 
 
Compound R1 R2 R3 IC50 AGS 
(μM) 4a H H H >100 
4b H Cl H 37.0 
4c CF3 H H >100 
4d H OCH3 H >100 
7a H H Glc >100 
7b H Cl Glc 78.8 
7c CF3 H Glc 73.0 
8a H Cl Dx 74.2 
8b CF3 H Dx 41.3 
9a H H Ru[9]aneS3 >100 
9b H Cl Ru[9]aneS3 >100 
9c CF3 H Ru[9]aneS3 >100 
9d H OCH3 Ru[9]aneS3 18.3 
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MRC-5, the safety range of this compound is quite narrow. Note that compound 4b has 
IC50 values of 45.0 and 37.0 μM against MRC-5 and AGS, respectively, which 
demonstrates its lack of selectivity.  
 Regarding the glycosylated derivatives with R3 = Glc, only compounds 7b and 7c 
were tested against MRC-5. None of these two exhibited a measurable IC50 value below 
100 μM against this cell line. Since 7b and 7c had a IC50 of, respectively, 78.8 and 73.0 
μM against AGS cell line, their safety margin is better than that of compound 4b. Thus, the 
insertion of R3 = Glc may be a good strategy to afford pyrazole derivatives with a better 
selectivity towards the AGS cancer cell line.  
 Compounds 8a and 8b were also tested against the MRC-5 cell line. Compound 8a 
didn’t present a measurable IC50 under 100 μM. Still, even though it didn’t compromise the 
MRC-5 viability by 50%, compound 8a was rather cytotoxic to MRC-5 cell lines at the 
concentration of 100 μM (see Figure 4.2). Still, the insertion of the R3 = Dx increased the 
safety margin of compound 8a when compared to its precursor, compound 4a. Compound 
8b has an IC50 value of 73.8 μM against MRC-5 cell line, which is almost two-fold higher 
than the IC50 value obtained with the AGS cancer cell line (41.3 μM). Thus, compound 8b 
presented a better selectivity than its precursor, compound 4c. Altogether, these results 
indicate that the insertion of the R3 = Dx group improves the selectivity of the pyrazole 
derivatives towards this cancer cell line.   
 Finally, within the ruthenium complexes, (9a-d) only one, complex 9d, was tested 
against the MRC-5 cell line, presenting a IC50 value of 62.2 μM. This result is 
approximately three-fold higher than the one obtained against the AGS cell line (IC50 = 
18.3 μM). Moreover, complex 9d also presented a better selectivity towards the AGS 
cancer cell line than its precursor, compound 4d. The reasonable safety margin and the 
potency of complex 9d against AGS cancer cell line makes it an interesting in vitro 
cytotoxic agent. Still, more tests need to be performed to evaluate unequivocally its safety 
toward healthy cell lines. 
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Figure 4.2 – Cytotoxic effect of compounds 4a-d, 7b-c, 8a,b and 9d against the MRC-5 cell line. 
The cells were incubated with five different concentrations of these compounds for 24h. The data is 
expressed as % of viability and represents the mean ± mean standard deviation from three to four 
independent experiments run in triplicate. * denotes p-value < 0.05, ** denotes p-value < 0.01, *** 
denotes p-value < 0.001 and **** denotes p-value < 0.0001. 
 
Table 4.2 – Structural representation and cytotoxic activity of compounds 4a-d, 7b-c, 8a,b and 9d 
against the MRC-5 cell line. The results are expressed as IC50 (μM). 
 
Compound R1 R2 R3 IC50 MRC-5 
(μM) 4a H H H 77.9 
4b H Cl H 45.0 
4c CF3 H H 72.0 
4d H OCH3 H 72.4 
7b H Cl Glc >100 
7c CF3 H Glc >100 
8a H Cl Dx >100 
8b CF3 H Dx 73.8 
9d H OCH3 Ru[9]aneS3 62.2 
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5.1.  Equipment, materials and solvents 
Commercial reagents used in this study suffered no purification prior to their use.  
All solvents were of analytical grade except when otherwise specified.  
Pyridine was dried by reflux over sodium hydroxide and then it was distilled and 
kept in molecular sieves (MS) 4Å. 
The acetone was dried with anhydrous sodium sulfate and kept in MS 4Å. 
Dichloromethane was dried by reflux over calcium hydride and then it was distilled 
and kept in MS 4Å. 
Progress of the reactions was monitored by TLC, using coated laminated sheets of 
silica gel 60 F254 plates from Riedel-de-Hans or silica gel 60 NHR / UV254 of Macherey 
Nigel.  
The purifications by preparative TLC were carried out on glass plates (20 × 20 cm) 
previously coated with a layer of silica gel 60 GF254 Riedel-de-Hans, with a thickness of 
0.5 mm and activated at 125°C for 12 hours. After elution of the compounds, the plates 
were observed under UV light at λ of 254 and / or 366 nm.  
The purifications by column chromatography were performed in a glass column 
using silica gel 60, Riedel-de-Hans, particle size 70-230 mesh as a support. Fractions were 
monitored by TLC and visualized by UV light (λ = 254 and/or 366 nm).  
The eluents used in either column chromatography or preparative TLC are 
mentioned in each case, as well as their volume ratio (proportion) in the case of mixtures 
of solvents.  
The values of the m.p. were determined on a Büchi melting point apparatus B-540 
and were not corrected.  
NMR spectra were acquired on a Bruker Avance 300 instrument operating at a 
frequency of 300.13 MHz for 1H and 75.47 MHz for 13C, or a Bruker Avance 500 
instrument operating at a frequency of 500.16 MHz for 1H and 125.77 MHz for 13C. 
Tetramethylsilane (TMS) was used as internal standard. The chemical shifts (δ, ppm) were 
obtained at r.t. and the deuterated solvent used is indicated in each case. For 1H NMR 
characterization, chemical shifts, multiplicity and coupling constants (J, Hz) are presented.  
The unequivocal assignment of the resonances of protons and carbons was 
performed using two-dimensional HSQC, HMBC, COSY and NOESY NMR experiments. 
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Fourier-transform infrared (FT-IR) spectra were collected as KBr pellets with 
typically 2 mg of sample and 200 mg of KBr using a Bruker Optics Tensor 27 FT-IR 
spectrophotometer (4000–400 cm−1 range, 64 scans, 2 cm−1 maximal resolution). 
Positive-ion ESI mass spectra and high resolution mass spectra [ESI(+)-HRMS] 
were performed using a Q Exactive Orbitrap mass spectrometer (Thermo Fischer 
Scientific, Bremen, Germany) controlled by THERMO  Xcalibur 4.1. The capillary voltage 
of the electrospray ionization (ESI) was set to 3000 V. The capillary temperature was 
250ºC. The sheath gas flow rate (nitrogen) was set to 5 (arbitrary unit as provided by the 
software settings). 
The AGS cancer cell line was purchased from the American Type Culture 
Collection (Manassas, Virginia, USA). The MRC-5 cell line was acquired from ECACC 
(Porton Down Salisbury, UK). 
The culture medium DMEM (1X) + GlutaMAX™-1 (Dulbecco’s Modified Eagle 
Medium) and MEM (1X) + GlutaMAX™-1 were acquired at Gibco®. PBS and trypsin 
(0.25%) were also purchased at Gibco®. 
The MTT solution was prepared in culture medium (5 mg/mL) and sterilized by 
filtration.  
The biological assays were performed on the ESCO® Airstream® Class II biological 
safety cabinet. 
5.2.  Protocols 
5.2.1.  Synthesis of (E)-3-styryl-4H-chromen-4-ones 
Only the (E)-3-styryl-4H-chromen-4-one (3a), (E)-3-(4-chlorostyryl)-4H-chromen-
4-one (3b) and (E)-3-(4-methoxystyryl)-4H-chromen-4-one (3d) were prepared in this 
work. The synthesis of these compounds was accomplished according to the procedure 
reported by Silva et al.90 To a solution of 4-oxo-4H-chromene-3-carbaldehyde (1) (300 mg, 
1.72 mmol) in dry pyridine (20 mL) were added 5 equiv. of the appropriate phenylacetic 
acid (2a, 2b or 2d) (8.60 mmol) and 1.5 equiv. of tert-BuOK (290 mg, 2.58 mmol). The 
mixture was stirred at 120 ºC under a nitrogen atmosphere. After 24 hours the reaction was 
monitored by TLC, using CH2Cl2 as eluent, and then it was stopped. The reaction mixture 
was cooled down to r.t.. Afterwards, the mixture was acidified with an HCl solution until 
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pH 2 was reached. The compound was extracted from the aqueous phase with 
dichloromethane and the organic and aqueous phases were separated. The organic layer 
was dried over anhydrous sodium sulfate. The solvent was removed under reduced 
pressure and a light brown solid was obtained.  The solid was dissolved in CH2Cl2 and 
purified by column chromatography using CH2Cl2 as eluent. Compounds 3a, 3b and 3d 
were dried in a vacuum pump and were obtained as a beige, pale beige and yellow solids, 
respectively in 73 %, 82 % and 34 % yields. 
(E)-3-(4-Chlorostyryl)-4H-chromen-4-one (3b) 
Pale beige solid, 82%, m.p. 152 – 154 ºC, (Lit.159 – 160 ºC)96 
1H NMR (CDCl3, 300.13 MHz): δ = 6.93 (dd, 1 H, J = 16.3, 0.6 
Hz, H-α), 7.32 (d, 2 H, J = 8.5 Hz, H-3’, 5’), 7.41-7.49 (m, 2 H, 
H-6, 8), 7.45 (d, 2 H, J = 8.5 Hz, H-2’, 6’) 7.63 (d, 1 H, J = 16.3 
Hz, H-β), 7.68 (ddd, 1 H, J = 8.5, 7.0, 1.7 Hz, H-7), 8.10 (s, 1 H, H-2), 8.30 (dd, 1 H, J = 
8.0, 1.7 Hz, H-5) ppm.  
13C NMR (CDCl3, 75.47 MHz): δ = 118.1 (C-8), 119.7 (C-α), 121.5 (C-3), 124.1 (C-4a), 
125.4 (C-6), 126.3 (C-5), 127.8 (C-2’, 6’), 128.8 (C-3’, 5’), 130,5 (C-β), 133.5 (C-4’), 
133.6 (C-7), 135.9 (C-1’), 153.4 (C-2), 155.8 (C-8a), 176.6 (C-4) ppm. 
(E)-3-(4-Methoxystyryl)-4H-chromen-4-one (3d) 
Yellow solid, 34%. 
1H NMR (CDCl3, 500.13 MHz): δ = 3.83 (s, 3 H, -OCH3), 
6.86 (dd, 1 H, J = 16.3, 0.7 Hz, H-α), 6.90 (d, 2 H, J = 8.7 
Hz, H-3’, 5’), 7.42 (ddd, 1 H, J = 8.2, 7.2, 1.0 Hz, H-6), 7.46-
7.48 (m, 1 H, H-8) 7.67 (d, 2 H, J = 8.7 Hz, H-2’, 6’), 7.55 (d, 1 H, J = 16.3 Hz, H-β), 7.67 
(ddd, 1 H, J = 8.5, 7.2, 1.5 Hz, H-7), 8.10 (d, 1 H, J = 0.7 Hz, H-2), 8.30 (dd, 1 H, J = 8.2, 
1.5 Hz, H-5) ppm.  
13C NMR [CDCl3, 75.47 MHz]: δ = 55.3 (-OCH3), 114.1 (C-3’, 5’), 116.8 (C-α), 118.1 
(C-8), 112.1 (C-3), 124.1 (C-4a), 125.2 (C-6), 126.3 (C-5), 127.9 (C-2’, 6’), 130.2 (C-1’), 
131.2 (C-β), 133.4 (C-7), 152.5 (C-2), 155.8 (C-8a), 159.5 (C-4’), 176.7 (C-4) ppm. 
MS (ESI+) m/z (%): 279.1. [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C18H14O3 (M+H)
+, 279.1016; found: 279.1011. 
77 
 
5.2.2.  Synthesis of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 
The synthesis of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles (4a, 4b and 4d) 
was performed following a procedure described by Silva et al.87 Briefly, 2 equiv of 
hydrazine hydrate, (0.15 mL, 2.66 mmol) were added to a solution of the appropriate (E)-
3-styryl-4H-chromen-4-one (3a, 3b or 3d)  (1.33 mmol) in methanol (80 mL). The reaction 
mixture was stirred at r.t., under nitrogen atmosphere, for 5h. The consumption of the 
starting material was monitored by TLC using CH2Cl2 as eluent. Then, the solvent was 
partially removed and the mixture was poured into 100 mL of CHCl3 and washed with 2 × 
100 mL of acidified water (pH 5). The organic layer was dried over anhydrous sodium 
sulfate and the solvent was evaporated to dryness. The (E)-3(5)-(2-hydroxyphenyl)-4-
styryl-1H-pyrazoles (4a, 4b and 4d) were dried in a vacuum pump and were obtained as 
pale beige, white and pale beige solids, respectively in  74%, 92% and 95% yields. 
(E)-4-(4-Chlorostyryl)-3(5)-(2-hydroxyphenyl)-1H-pyrazole (4b) 
White solid, m.p. 169.4 – 169.9 ºC, (Lit.: 163 – 164 ºC),87 92%. 
1H NMR (CDCl3, 300.13 MHz): δ = 6.84 (d, 1 H, J = 16.4 Hz, H-β), 
6.97 (dt, 1 H, J = 7.6, 1.3 Hz, H-5’), 7.08 (dd, 1 H, J = 8.4, 1.3 Hz, H-
3’), 7.12 (d, 1 H, J = 16.4 Hz, H-α), 7.28-7.35 (m, 1 H, H-4’), 7.32 (d, 
2 H, J = 8.6 Hz, H-2’’,6’’), 7.39 (d, 2 H, J = 8.6 Hz, H-3’’,5’’), 7.58 
(dd, 1 H, J = 7.6, 1.6 Hz, H-6’), 7.85 (broad s, 1 H, H-5) ppm.  
13C NMR (CDCl3, 75.47 MHz): δ = 117.0 (C-3’), 117.2 (C-1’), 120.5 (C-4), 119.5 (C-α), 
119.6 (C-5’), 127.5 (C-2’’,6’’), 127.7 (C-5), 128.5 (C-6’), 128.7 (C-β), 128.9 (C-3’’,5’’), 
129.6 (C-4’), 133.2 (C-4’’), 135.8 (C-1’’), 148.0 (C-3), 155.6 (C-2’) ppm. 
FT-IR (KBr, ν̄max (cm-1)): 3264 s (νN–H), 1635 m (νC=C), 1586 s (νC=N), 1154 w (νN–
N), 1087 s (νC–OH), 966 s (ωCα=Cβ), 752 vs (νC–H), 709 s (νC–H). 
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(E)-3(5)-(2-Hydroxyphenyl)-4-(4-methoxystyryl)-1H-pyrazole (4d) 
Pale beige solid, m.p. 157.3-158.5 ºC, 95%. 
1H NMR [(CD3)2CO, 300.13 MHz]: δ = 3.83 (s, 3 H, -OCH3), 6.84 (d, 1 
H, J = 16.2, Hz, H-β), 6.91 (d, 2 H, J = 8.8 Hz, H-3’’, 5’’), 6.92-6.99 (m, 
1 H, H-5’), 7.02 (d, 1 H, J = 16.2 Hz, H-α), 7.07 (dd, 1 H, J = 8.0, 1.2 
Hz, H-3’), 7.26 (ddd, 1 H, J = 8.0, 7.7, 1.6 Hz, H-4’), 7.41 (d, 2 H, J = 
8.8 Hz, H-2’’, 6’’), 7.64 (dd, 1 H, J = 7.8, 1.6 Hz, H-6’), 7.81 (s, 1 H, H-
5) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 55.4 (-OCH3), 116.8 (C-3’’, 5’’), 116.8 (C-α), 
117.0 (C-3’), 117.4 (C-1’), 118.8 (C-4), 119.5 (C-5’), 127.5 (C-2’’,6’’, 5), 128.5 (C-6’), 
129.4 (C-4’), 129.6 (C-β), 130.1 (C-1’’), 148.0 (C-3), 155.6 (C-2’), 159.3 (C-4’’) ppm. 
FT-IR (KBr, ν̄max (cm-1)): 3127 m (νN–H), 1601 m (νC=C), 1576 m (νC=N), 1152 m (νN–
N), 1086 m (νC–OH), 960 s (ωCα=Cβ), 770 s (νC–H), 701 m (νC–H). 
MS (ESI+) m/z (%): 293.1 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C18H16N2O2 (M+H)
+, 293.1277; found: 293.1285. 
5.2.3.  Glycosylation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 
According to the Koenigs-Knorr method,88 3 equiv. of Ag2CO3 (278 mg, 1.02 
mmol), 0.15 equiv. of AgOTf (12.9 mg, 0.05 mmol) and 1.5 equiv of 2,3,4,6-tetra-O-
acetyl--D-glucopyranosyl bromide (213.8 mg, 0.52 mmol) were added to a solution of the 
appropriate (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazole (0.34 mmol) (4a-d) in 
CH2Cl2 (8 mL). MS 4Å (3.4 g) were added to guarantee anhydrous conditions. The mixture 
was stirred at r.t., under a nitrogen atmosphere for 7 to 10 days. After that period, the 
reaction mixture was filtered, the solid was washed with CH2Cl2 and the solvent was 
evaporated to dryness. The organic residue was dissolved in CH2Cl2 and purified by TLC 
using CH2Cl2:acetone (9:1) as eluent. After purification the obtained compounds were 
dried in a vacuum pump and were analysed by 1H NMR spectroscopy. According to the 1H 
NMR data, the compound with lower r.f. corresponds to compound 5 and the compound 
with higher r.f. is compound 6. Compounds 5a-d were obtained as pale beige solids with 
respectively, 20 %, 19 %, 41 % and 12 % yields (see Table 2.1, entry 1, 3, 6 and 7). 
Compounds 6 were obtained as: pale yellow oil (6a), yellow oil (6b) and pale yellow oils 
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(6c and 6d) with yields of 52 %, 50 %, 11 % and 39% (consult Table 2.1, entry 1, 3, 6 and 
7).  
 (E)-1-[β-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-1H-
pyrazole (5a) 
Pale beige solid, 20%. 
1H NMR [(CD3)2CO, 500.13 MHz]: δ = 1.98 (s, 3 H, -COCH3), 
2.01 (s, 3 H, -COCH3), 2.04-2.10 (m, 6 H, 2 × -COCH3), 3.81-
4.34 (m, 3 H, 6’’’-CH2OCOCH3,5’’’), 5.29 (t, 1 H, J = 9.5 Hz, H-
4’’’), 5.56 (t, 1 H, J = 9.5 Hz, H-3’’’), 5.79 (t, 1 H, J = 9.5 Hz, H-
2’’’), 6.02 (d, 1 H, J = 9.5 Hz, H-1’’’), 6.98 (ddd, 1 H, J = 7.5, 
7.6, 1.0 Hz, H-5’), 7.02 (dd, 1 H, J = 7.7, 1.0 Hz, H-3’), 7.05 (d, 1 
H, J = 16.3 Hz, H-β), 7.21 (d, 1 H, J = 16.3 Hz, H-α), 7.27-7.31 
(m, 2 H, H-4’,4’’), 7.38 (t, 2 H, J = 7.5 Hz, H-3’’,5’’), 7.56 (d, 2 H, J = 7.5 Hz, H-2’’,6’’), 
7.64 (dd, 1 H, J = 7.6, 1.6 Hz, H-6’), 8.43 (s, 1 H, H-5), 9.68 (s, 1 H, 2’-OH) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.2 (-COCH3), 20.5 (-COCH3), 20.6 (2 × -
COCH3), 62.7 (C-6’’’), 68.4 (C-4’’’), 71.0 (C-2’’’), 73.7 (C-3’’’), 75.0 (C-5’’’), 87.3 (C-
1’’’), 117.6 (C-3’), 118.3 (C-1’), 119.3 (C-α), 120.2 (C-5’), 120.7 (C-4), 127.1 (C-2’’,6’’), 
128.4 (C-4’’), 129.5 (C-3’’, 5’’), 129.8 (C-6’), 129.9 (C-5), 130.5 (C-4’), 130.9 (C-β), 
149.4 (C-1’’), 156.7 (C-3), 156.7 (C-2’), 169.4 (-COCH3), 170.0 (-COCH3), 170.3 (-
COCH3), 170.7 (-COCH3) ppm. 
 (E)-1-[-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-4-(4-chlorostyryl)-3-(2-
hydroxyphenyl)-1H-pyrazole (5b) 
Pale beige solid, 19%.  
1H NMR [(CD3)2CO, 300.13 MHz]: δ = 1.87 (s, 3 H, -COCH3), 
2.00 (s, 3 H, -COCH3), 2.02 (s, 3 H, -COCH3), 2.04-2.07 (m, 3 H, 
-COCH3), 4.16-4.36 (m, 3 H, 6’’’-CH2OCOCH3,5’’’), 5.28 (t, 1 
H, J = 9.5 Hz, H-4’’’), 5.55 (t, 1 H, J = 9.5 Hz, H-3’’’), 5.78 (t, 1 
H, J = 9.5 Hz, H-2’’’), 6.01 (d, 1 H, J = 9.5 Hz, H-1’’’), 6.97 (t, 1 
H, J = 7.9 Hz, H-5’), 7.04 (d, 1 H, J = 16.3 Hz, H-β), 7.00-7.09 
(m, 1 H, H-3’), 7.23 (d, 1 H, J = 16.3 Hz, H-α), 7.29 (ddd, 1 H, J 
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= 7.7, 7.9, 1.6 Hz, H-4’), 7.40 (d, 2 H, J = 8.2 Hz, H-3’’,5’’), 7.58 (d, 2 H, J = 8.2 Hz, H-
2’’,6’’), 7.63 (dd, 1 H, J = 7.9, 1.6 Hz, H-6’), 8.43 (s, 1 H, H-5), 9.63 (s, 1 H, 2’-OH) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.2 (-COCH3), 20.5 (-COCH3), 20.6 (2 × -
COCH3), 62.7 (C-6’’’), 68.8 (C-4’’’), 71.1 (C-2’’’), 73.7 (C-3’’’), 75.0 (C-5’’’), 87.3 (C-
1’’’), 117.6 (C-3’), 118.3 (C-1’), 120.3 (C-5’), 120.3 (C-α), 120.5 (C-4), 128.7 (C-2’’, 6’’), 
129.4 C- β), 129.6 (C-3’’, 5’’), 130.0 (C-6’), 130.1 (C-5), 130.5 (C-4’), 133.3 (C- 4’’), 
137.2 (C-1’’), 149.4 (C-3), 156.6 (C-2’), 169.4 (-COCH3), 170.0 (-COCH3), 170.3 (-
COCH3), 170.7 (-COCH3) ppm. 
MS (ESI+) m/z (%): 627.2 [(M+H)+, 35Cl] (100). 
HRMS (ESI+) m/z calcd for C31H31ClN2O10 (M+H)
+, 627.1736; found: 627.174 
(E)-1-[β-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-(2-
trifluoromethylstyryl)-1H-pyrazole (5c) 
Pale beige solid, m.p. 76.7-79.4 ºC, 11%. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 1.88 (s, 3 H, -COCH3), 
1.98-2.10 (m, 9 H, 3 × -COCH3), 4.19-4.34 (m, 3 H, 6’’’-
CH2OCOCH3,5’’’), 5.29 (t, 1 H, J = 9.5 Hz, H-4’’’), 5.55 (t, 1 H, 
J = 9.5 Hz, H-3’’’), 5.83 (t, 1 H, J = 9.5 Hz, H-2’’’), 6.03 (d, 1 H, 
J = 9.5 Hz, H-1’’’), 6.97 (dt, 1 H, J = 7.6, 1.1 Hz, H-5’), 7.02 (dd, 
1 H, J = 8.0, 1.1 Hz, H-3’), 7.25 (d, 1 H, J = 16.0 Hz, H-α), 7.30 
(ddd, 1 H, J = 8.0, 7.6, 1.6 Hz, H-4’), 7.32 (d, 1 H, J = 16.0 Hz, 
H-β), 7.50 (t, 1 H, J = 7.8 Hz, H-4’’), 7.59 (dd, 1 H, J = 7.6, 1.6 Hz, H-6’), 7.68 (t, 1 H, J = 
7.8 Hz, H-5’’), 7.75 (d, 1 H, J = 7.8 Hz, H-3’’), 7.96 (d, 1 H, J = 7.8 Hz, H-6’’), 8.52 (s, 1 
H, H-5), 9.53 (s, 1 H, 2’-OH) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.2 (-COCH3), 20.5 (-COCH3), 20.6 (2 × -
COCH3), 62.7 (C-6’’’), 68.8 (C-4’’’), 71.0 (C-2’’’), 73.7 (C-3’’’), 75.0 (C-5’’’), 87.3 (C-
1’’’), 117.6 (C-3’), 118.3 (C-1’), 120.3 (C-5’), 124.0 (C-α), 125.5 (C-4), 126.6 (q, J = 5.8 
Hz, C-3’’), 127.4 (q, J = 32.6 Hz, C-2’’), 128.1 (C-6’’), 128.4 (C-4’’), 130.1 (C-6’), 130.6 
(C-5, 4’), 130.6 (C- β), 133.4 (C-5’’), 137.1 (C-1’’), 149.7 (C-3), 156.6 (C-2’), 169.5 (-
COCH3), 170.0 (-COCH3), 170.3 (-COCH3), 170.7 (-COCH3) ppm. 
 
Note: It was not possible to assign the CF3 carbon resonance. 
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(E)-1-[β-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-3-(2-hydroxyphenyl)-4-(4-
methoxystyryl)-1H-pyrazole (5d) 
 Pale beige solid, 12%. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 1.87 (s, 3 H, -COCH3), 
2.00 (s, 3 H, -COCH3), 2.02 (s, 3 H, -COCH3), 2.04-2.07 (m, 3 H, 
-COCH3), 3.83 (s, 3 H, 4’’-OCH3) 4.18-4.34 (m, 3 H, 6’’’-
CH2OCOCH3,5’’’), 5.29 (t, 1 H, J = 9.5 Hz, H-4’’’), 5.48 (t, 1 H, 
J = 9.3 Hz, H-3’’’*), 5.55 (t, 1 H, J = 9.5 Hz, H-3’’’), 5.68 (t, 1 H, 
J = 9.3 Hz, H-2’’’*), 5.78 (t, 1 H, J = 9.5 Hz, H-2’’’), 5.94 (d, 1 
H, J = 9.3 Hz, H-1’’’*), 6.00 (d, 1 H, J = 9.5 Hz, H-1’’’), 6.70 (d, 1 H, J = 12.0 Hz, H-
α/β*), 6.82 (d, 2 H, J = 8.9 Hz, H-3’’,5’’*), 6.87-6.90 (m, 1 H, H-5’*), 6.94-6.98 (m, 1 H, 
H-5’), 6.95 (d, 2 H, J = 8.7 Hz, H-3’’,5’’), 6.98-7.02 (m, 1 H, H-3’), 6.98 (d, 1 H, J = 16.2 
Hz, H-α/β), 7.05 (d, 1 H, J = 16.2 Hz, H-α/β), 7.22-7.26 (m, 1 H, H-4’*), 7.26-7.30 (m, 1 
H, H-4’), 7.50 (d, 2 H, J = 8.7 Hz, H-2’’,6’’), 7.65 (dd, 1 H, J = 7.8, 1.6 Hz, H-6’), 8.37 (s, 
1 H, H-5), 9.74 (s, 1 H, 2’-OH) ppm.  
MS (ESI+) m/z (%): 693.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C32H34N2O11 (M+H)
+, 623.2239; found: 623.2235. 
Note: the “*” symbol corresponds to the proton duplications correspondent to the minority 
cis isomer. A full NMR characterization wasn’t presented due to the presence of the two 
isomers. The structure displayed here only represents the trans isomer. 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazole (6a) 
Pale yellow oil, 52%. 
1H NMR [(CD3)2CO, 300.13 MHz]: δ = 2.05-2.10 (m, 6 H, 2 × 
-COCH3), 2.13 (br s, 3 H, -COCH3), 2.19 (s, 3 H, 2’’’-CH3), 
4.23 (t, 1 H, J = 5.2 Hz, H-7a’’’), 4.26-4.31 (m, 2 H, 5’’’-
CH2OCOCH3), 4.46 (ddd, 1 H, J = 5.2, 2.8, 0.9 Hz, H-5’’’), 4.97 
(ddd, 1 H, J = 9.1, 1.8, 0.9 Hz, H-6’’’), 5.25 (t, 1 H, J = 2.8 Hz, 
H-7’’’), 6.18 (d, 1 H, J = 5.2 Hz, H-3a’’’), 6.96-6.98 (m, 1 H, H-
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5’), 7.02 (dd, 1 H, J = 7.8, 1.1 Hz, H-3’), 7.07 (d, 1 H, J = 16.5 Hz, H-β), 7.24 (d, 1 H, J = 
16.5 Hz H-α), 7.27-7.32 (m, 2 H, H-4’,4’’), 7.38 (t, 2 H, J = 7.4 Hz, H-3’’,5’’), 7.55 (d, 2 
H, J = 7.4 Hz, H-2’’,6’’), 7.67 (dd, 1 H, J = 7.8, 1.6 Hz, H-6’), 8.37 (s, 1 H, H-5), 10.12 (s, 
1 H, 2’-OH) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.2 (-COCH3), 20.5 (-COCH3), 20.6 (-COCH3), 
24.3 (2’’’-CH3), 63.9 (5’’’-CH2OCOCH3), 68.4 (C-7a’’’), 68.8 (C-6’’’), 70.1 (C-7’’’), 73.8 
(C-5’’’), 98.9 (C-3a’’’), 114.5 (C-2’’’), 117.6 (C-3’), 118.4 (C-4), 119. 4 (C-α), 119.5 (C-
1’), 120.2 (C-5’), 127.1 (C-2’’,6’’), 127.6 (C-5), 128.3 (C-4’’), 129.5 (C-3’’,5’’,6’), 130.3 
(C-4’), 130.7 (C-β), 138.4 (C-1’’), 149.4 (C-3), 156.8 (C-2’), 169.5 (-COCH3), 170.1 (-
COCH3), 170.8 (-COCH3) ppm. 
MS (ESI+) m/z (%): 593.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C31H32N2O10 (M+H)
+, 593.2131; found: 593.213. 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)-1H-
pyrazole (6b) 
Pale yellow oil, 50%. 
1H NMR [(CD3)2CO, 300.13 MHz]: δ = 2.05-2.07 (m, 6 H, 2 × 
-COCH3), 2.13 (br s, 3 H, -COCH3), 2.19 (s, 3 H, 2’’’-CH3), 
4.24 (t, 1 H, J = 5.2 Hz, H-7a’’’), 4.25-4.33 (m, 2 H, 5’’’-
CH2OCOCH3), 4.46 (ddd, 1 H, J = 5.2, 2.8, 0.9 Hz, H-5’’’), 4.99 
(ddd, 1 H, J = 9.8, 2.0, 0.9 Hz, H-6’’’), 5.26 (t, 1H, J = 2.8 Hz, 
H-7’’’), 6.17 (d, 1 H, J = 5.2 Hz, H-3a’’’), 6.97 (ddd, 1 H, J = 
7.7, 7.6, 1.1 Hz, H-5’), 7.02 (dd, 1 H, J = 8.0, 1.1 Hz, H-3’), 7.05 
(d, 1 H, J = 16.2 Hz, H-β), 7.26 (d, 1 H, J = 16.2 Hz, H-α), 7.29 
(ddd, 1 H, J = 8.0, 7.6, 1.6 Hz, H-4’), 7.39 (d, 2 H, J = 8.6 Hz, H-3’’,5’’), 7.56 (d, 2 H, J = 
8.6 Hz, H-2’’,6’’), 7.65 (dd, 1 H, J = 7.7, 1.6 Hz, H-6’), 8.38 (s, 1 H, H-5), 10.08 (s, 1 H, 
2’-OH) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.6 (2 × -COCH3), 20.8 (-COCH3), 24.3 (2’’’-
CH3), 63.8 (5’’’-CH2OCOCH3), 68.4 (C-7a’’’), 68.8 (C-6’’’), 70.1 (C-7’’’), 73.8 (C-5’’’), 
98.9 (C-3a’’’), 114.5 (C-2’’’), 117.5 (C-3’), 118.4 (C-1’), 119.3 (C-4), 120.2 (C-5’), 120.4 
(C-α), 127.7 (C-5), 128.5 (C-2’’,6’’), 129.2 (C-β), 129.5 (C-3’’,5’’,6’), 130. (C-4’), 133.2 
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(C-4’’), 137.2 (C-1’’), 149.5 (C-3), 156.7 (C-2’), 169.5 (7’’’-COCH3), 170.1 (6’’’-
COCH3), 170.8 (5’’’-CH2OCOCH3) ppm. 
MS (ESI+) m/z (%) = 627.2 [(M+H)+, 35Cl] (100), 629.2 [(M+H)+, 37Cl] 
HRMS (ESI+) m/z calcd for C31H31ClN2O10 (M+H)
+, 627.1742; found: 627.174. 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-(2-trifluoromethylstyryl)-
1H-pyrazole (6c) 
Yellow oil, 41%. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 2.05-2.07 (m, 6 H, 2 × 
-COCH3), 2.13 (br s, 3 H, -COCH3), 2.19 (s, 3 H, 2’’’-CH3), 
4.21 (t, 1 H, J = 5.2 Hz, H-7a’’’), 4.25-4.31 (m, 2 H, 5’’’-
CH2OCOCH3), 4.47 (ddd, 1 H, J = 5.2, 2.3, 0.8 Hz, H-5’’’), 4.98 
(ddd, 1 H, J = 8.5, 2.0, 0.8 Hz, H-6’’’), 5.25 (t, 1 H, J = 2.3 Hz, 
H-7’’’), 6.16 (d, 1 H, J = 5.2 Hz, H-3a’’’), 6.96 (dt, 1 H, J = 7.6, 
1.2 Hz, H-5’), 7.02 (dd, 1 H, J = 8.2, 1.2 Hz, H-3’), 7.26 (d, 1 H, 
J = 16.0 Hz, H-α), 7.28-7.34 (m, 2 H, H-4’,β), 7.50 (t, 1 H, J = 7.8 Hz, H-4’’), 7.61 (dd, 1 
H, J = 7.6, 1.6 Hz, H-6’), 7.68 (t, 1 H, J = 7.8 Hz, H-5’’), 7.75 (d, 1 H, J = 7.8 Hz, H-3’’), 
7.93 (d, 1 H, J = 7.8 Hz, H-6’’), 8.43 (s, 1 H, H-5) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 20.6-20.8 (3 × CO2CH3), 24.4 (2’’’-CH3), 63.9 
(CH2CO2CH3), 68.4 (C-7a’’’), 68.8 (C-6’’’), 70.1 (C-7’’’), 73.8 (C-5’’’), 98.9 (C-3a’’’), 
114.6 (C-2’’’), 117.5 (C-3’), 118.4 (C-1’), 119.1 (C-4), 120.3 (C-5’), 124.4 (C-α), 128.0 
(C-5), 128.2 (C-6’’), 128.4 (C-4’’), 129.8 (C-6’), 130.5 (C-4’, β), 133.4 (C-5’’), 137.2 (C-
1’’), 149.8 (C-3), 156.7 (C-2’), 169.5 (7’’’-COCH3), 170.2 (6’’’-COCH3), 170.8 (5’’’-
CH2OCOCH3) ppm.  
MS (ESI+) m/z (%): 661.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C32H31F3N2O10 (M+H)
+, 661.1998; found: 661.2004. 
 
Note: It was not possible to unequivocally assign the resonances of C-2’’, C-3’’ and CF3 
carbons due to the very low intensity of the corresponding signals.  
 
 
84 
 
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-(4-methoxystyryl)-1H-
pyrazole (6d) 
 
Pale beige solid, 77% 
1H NMR [(CD3)2CO, 300.13 MHz]: δ = 3.83 (s, 3 H, 4’’-
OCH3), 3.99-4.07 (m, 2 H, 5’’’*-CH2OCOCH3), 4.24-4.31 (m, 2 
H, 5’’’-CH2OCOCH3), 4.42 (ddd, 1 H, J = 5.4, 3.1, 0.8 Hz, H-
5’’’), 4.89 (ddd, 1 H, J = 9.6, 3.1, 0.8 Hz, H-6’’’), 5.14 (t, 1 H, J 
= 2.9 Hz, H-7’’’), 5.64 (d, 1 H, J = 5.6 Hz, H-3a’’’*), 5.75 (d, 1 
H, J = 5.4 Hz, H-3a’’’), 6.93-7.01 (m, 2 H, H-3’,5’), 6.95 (d, 2 
H, J = 8.7 Hz, H-3’’,5’’), 6.96 (d, 1 H, J = 16.2 Hz, H-α/β), 7.15 
(d, 1 H, J = 16.2 Hz, H-α/β), 7.25 (ddd, 1 H, J = 8.2, 7.7, 1.5 Hz, H-4’), 7.50 (d, 2 H, J = 
8.7 Hz, H-2’’,6’’), 7.69 (d, 1 H, J = 7.5 Hz, H-6’), 8.16 (s, 1 H, H-5), 9.74 (s, 1 H, 2’-OH) 
ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
HRMS (ESI+) m/z calcd for C32H34N2O11 (M+H)
+, 623.2237; found: 623.2235. 
Note: the “*” symbol indicates the resonances of the protons correspondent to the less 
abundant isomer. The full NMR characterization wasn’t presented due to the presence of 
the two isomers. The structure presented here only represents the trans isomer. 
5.2.4.  Deprotection of the glycosylated products 5 and 6 
The deprotection of the sugar moiety of compounds 5a-d and 6a, 6c and 6d was 
achieved using the Amberlite® IRA-400(OH) resin, as reported by Pathak et al.95 However, 
we only had access to Amberlite® IRA-400(Cl) resin. Consequently, a pre-treatment of this 
resin was required prior to its use in the reaction. Amberlite® IRA-400(Cl) (110.3 mg) was 
rinsed with 6 mL of a NaOH 1M solution, 6 mL of H2O and 6 mL of MeOH, in this order, 
under reduced pressure. These volumes were added 2 mL at the time, to ensure the resin 
was properly treated. In some cases, the volume of H2O was increased, to guarantee that 
the resin was properly washed and the pH of H2O after passing through the resin was 
around 7. Afterwards, to a solution of 5a-d or 6a-d (0.070 mmol) in 11 mL of MeOH, it 
was added the Amberlite® IRA-400(OH) resin (110.3 mg). The reaction was kept at 30 ºC, 
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under constant stirring for 4 hours or 21 hours. The reaction was monitored by TLC, using 
CH2CL2:acetone (9:1) as eluent. The resin was removed through a filtration unit and 
washed with MeOH. Compounds 7a-d and 8a,b were dried in a vacuum pump. 
Compounds 7a-d were obtained as pale beige solids with a 68 %, 67 %, 77 % and 30% of 
yield, respectively. Compound 8b was obtained as a pale beige solid in a quantitative yield. 
(E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-styryl-1H-pyrazole (7a) 
Pale beige solid, m.p. 114.4-118.4 ºC, 68% 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 3.58 (t, 1 H, J = 9.3 Hz, H-
4’’’), 3.63 (ddd, 1 H, J = 9.3, 4.8, 1.8 Hz, H-5’’’), 3.67 (t, 1 H, J = 
9.3 Hz, H-3’’’), 3.73 (dd, 1 H, J = 11.9, 4.8 Hz, 6’’’-CH2OH), 3.89 
(dd, 1 H, J = 11.9, 1.8 Hz, 6’’’-CH2OH), 4.07 (t, 1 H, J = 9.3 Hz, H-
2’’’), 5.44 (d, 1 H, J = 9.3 Hz, H-1’’’), 6.98 (t, 1 H, J = 7.6 Hz, H-
5’), 7.00 (d, 1 H, J = 8.4 Hz, H-3’), 7.07 (d, 1 H, J = 16.2 Hz, H-β), 
7.25-7.29 (m, 3 H, H-4’,4’’,α), 7.38 (t, 2 H, J = 7.6 Hz, H-3’’,5’’), 7.56 (d, 2 H, J = 7.6 Hz, 
H-2’’,6’’), 7.68 (dd, 1 H, J = 7.6, 1.2 Hz, H-6’), 8.35 (s, 1 H, H-5) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 62.5 (C-6’’’), 71.0 (C-4’’’), 73.3 (C-2’’’), 78.5 
(C-3’’’), 80.4 (C-5’’’), 90.4 (C-1’’’), 117.5 (C-3’), 118.6 (C-1’), 119.6 (C-α), 119.8 (C-5’), 
120.7 (C-4), 127.1 (C-2’’,6’’), 128.2 (C-4’’), 129.5 (C-6’), 129.5 (C-3’’, 5’’), 130.0 (C-5), 
130.2 (C-4’), 130.5 (C-β), 148.5 (C-1’’), 151.7 (C-3), 156.8 (C-2’) ppm. 
MS (ESI+) m/z (%): 425.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C23H24N2O6 (M+H)
+, 425.1706; found: 425.1707. 
(E)-4-(4-Chlorostyryl)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-1H-pyrazole (7b) 
Pale beige solid, 67%.  
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 3.57 (t, 1 H, J = 9.1 Hz, H-
4’’’), 3.63 (ddd, 1 H, J = 9.1, 5.3, 2.2 Hz, H-5’’’), 3.67 (t, 1 H, J = 
9.1 Hz, H-3’’’), 3.72 (dd, 1 H, J = 12.0, 5.3 Hz, 6’’’-CH2OH), 3.89 
(dd, 1 H, J = 12.0, 2.2 Hz, 6’’’-CH2OH), 4.06 (t, 1 H, J = 9.1 Hz, H-
2’’’), 5.44 (d, 1 H, J = 9.1 Hz, H-1’’’), 6.97 (ddd, 1 H, J = 7.8, 7.5, 
1.0 Hz, H-5’), 7.00 (dd, 1 H, J = 7.8, 1.0 Hz, H-3’), 7.07 (d, 1 H, J = 
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16.3 Hz, H-β), 7.26-7.30 (m, 1 H, H-4’), 7.29 (d, 1 H, J = 16.3 Hz, H-α), 7.40 (d, 2 H, J = 
8.5 Hz, H-3’’,5’’), 7.59 (d, 2 H, J = 8.5 Hz, H-2’’,6’’), 7.67 (dd, 1 H, J = 7.8, 1.5 Hz, H-
6’), 8.37 (s, 1 H, H-5) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 62.5 (C-6’’’), 71.0 (C-4’’’), 73.3 (C-2’’’), 78.5 
(C-3’’’), 80.4 (C-5’’’), 90.4 (C-1’’’), 117.5 (C-3’), 118.5 (C-1’), 119.6 (C-5’), 120.1 (C-α), 
120.6 (C-4), 128.6 (C-2’’,6’’), 129.0 (C-β), 129.5 (C-3’’,5’’, 6’), 130.1 (C-4’), 130.2 (C-5), 
137.2 (C-4’’), 137.4 (C-1’’), 148.6 (C-3), 156.8 (C-2’) ppm. 
MS (ESI+) m/z (%): 459.1 [(M+H)+, 35Cl] (100), 461.1 [(M+H)+, 37Cl]. 
HRMS (ESI+) m/z calcd for C23H23ClN2O6 (M+H)
+, 459.1314; found: 459.1317. 
(E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-(2-trifluoromethylstyryl)-1H-
pyrazole (7c) 
Pale beige solid, 77%. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 3.56 (t, 1 H, J = 9.1 Hz, H-
4’’’), 3.62 (ddd, 1 H, J = 9.1, 5.3, 2.0 Hz, H-5’’’), 3.66 (t, 1 H, J = 
9.1 Hz, H-3’’’), 3.72 (dd, 1 H, J = 12.0, 5.3 Hz, 6’’’-CH2OH), 3.89 
(dd, 1 H, J = 12.0, 2.0 Hz, 6’’’-CH2OH), 4.09 (t, 1 H, J = 9.1 Hz, H-
2’’’), 5.47 (d, 1 H, J = 9.1 Hz, H-1’’’), 6.97 (dt, 1 H, J = 7.6, 1.0 
Hz, H-5’), 7.01 (dd, 1 H, J = 8.0, 1.0 Hz, H-3’), 7.28 (ddd, 1 H, J = 
8.0, 7.6, 1.7 Hz, H-4’), 7.30-7.33 (m, 2 H, H-α,β), 7.50 (t, 1 H, J = 7.8 Hz, H-4’’), 7.65 
(dd, 1 H, J = 7.6, 1.7 Hz, H-6’), 7.68 (t, 1 H, J = 7.8 Hz, H-5’’), 7.75 (d, 1 H, J = 7.8 Hz, 
H-3’’), 7.97 (d, 1 H, J = 7.8 Hz, H-6’’),  8.45 (s, 1 H, H-5) ppm.  
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 62.5 (C-6’’’), 71.0 (C-4’’’), 73.2 (C-2’’’), 78.5 
(C-3’’’), 80.5 (C-5’’’), 90.4 (C-1’’’), 117.5 (C-3’), 118.4 (C-1’), 119.4 (C-4), 120.2 (C-4), 
124.4 and 125.1 (C-α,β), 126.6 (q, J = 5.7 Hz, C-3’’), 126.9 (q, J = 29.6 Hz, C-2’’), 128.2 
(C-6’’), 128.3 (C-4’’), 129.7 (C-6’), 130.3 (C-4’), 131.0 (C-5), 137.2 (C-5’’), 144.7 (C-
1’’), 148.9 (C-3), 156.7 (C-2’) ppm. 
MS (ESI+) m/z (%): 493.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C24H23F3N2O6 (M+H)
+, 493.1579; found: 493.1581. 
 
Note: It was not possible to unequivocally assign the resonance of CF3 carbon due to the 
very low intensity of the signals. 
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(E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-(4-methoxystyryl)-1H-pyrazole (7d) 
 Pale beige solid, 30 %. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 3.42 (t, 1 H, J = 8.9 Hz, 
H-4’’’), 3.47-3.61 (m, 1 H, H-5’’’), 3.63-3.69 (m, 1 H, H-3’’’), 3.69 
(s, 3 H, 4’’-OCH3), 3.69-3.79 (m, 2 H, 6’’’-CH2OH), 3.91 (t, 1 H, J 
= 8.9 Hz, H-2’’’), 4.08 (t, 1 H, J = 4.9 Hz, H-2’’’*), 5.28 (d, 1 H, J 
= 8.9 Hz, H-1’’’), 5.57 (d, 1 H, J = 4.9 Hz, H-1’’’*), 6.32 (d, 1 H, J 
= 11.9 Hz, H-α/β*), 6.52 (d, 1 H, J = 11.9 Hz, H-α/β*), 6.81 (d, 2 
H, J = 8.7 Hz, H-3’’,5’’), 6.82-6.86 (m, 2 H, H-3’,5’), 6.86 (d, 1 H, J = 16.4 Hz, H-α/β), 
6.98 (d, 1 H, J = 16.4 Hz, H-α/β), 7.12 (dt, 1 H, J = 7.8, 1.6 Hz, H-4’), 7.36 (d, 2 H, J = 8.7 
Hz, H-2’’,6’’), 7.54 (dd, 1 H, J = 7.8, 1.6 Hz, H-6’), 8.15 (s, 1 H, H-5) ppm.  
MS (ESI+) m/z (%): 455.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C24H26N2O7 (M+H)
+, 455.1803; found: 455.1813.  
Note: the “*” symbol indicates the resonances of the protons correspondent to the less 
abundant cis isomer. A full NMR characterization wasn’t presented due to the presence of 
the two isomers. The structure displayed here only represents the trans isomer. 
(E)-4-(4-Chlorostyryl)-1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-hydroxymethyl-2-
methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-3-(2-hydroxyphenyl)-1H-
pyrazole (8a) 
White solid, quantitative. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 2.19 (s, 3 H, 2’’’-CH3), 
3.66 (dd, 1 H, J = 8.5, 3.9 Hz, H-6’’’), 3.73-3.78 (m, 2 H, H-5’’’, 
5’’’-CH2OH), 3.86 (d, 1 H, J = 10.0 Hz, 5’’’-CH2OH), 4.03 (t, 1 H, 
J = 3.9 Hz, H-7’’’), 4.30 (t, 1 H, J = 4.6 Hz, H-7a’’’), 5.98 (d, 1 H, 
J = 4.6 Hz, H-3a’’’), 6.97 (t, 1 H, J = 7.6 Hz, H-5’), 7.01 (d, 1 H, J 
= 8.3 Hz, H-3’), 7.10 (d, 1 H, J = 16.1 Hz, H-β), 7.27-7.30 (m, 1 H, 
H-4’), 7.29 (d, 1 H, J = 16.1 Hz, H-α), 7.40 (d, 2 H, J = 8.5 Hz, H-
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3’’, 5’’), 7.58 (d, 2 H, J = 8.5 Hz, H-2’’, 6’’), 7.67 (dd, 1 H, J = 7.6, 1.1 Hz, H-6’), 8.38 (s, 
1 H, H-5), 10.25 (br s, 1 H, 2’-OH) ppm. 
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 24.9 (2’’’-CH3), 63.0 (5’’’-CH2OH), 70.4 (C-
6’’’), 73.7 (C-7’’’), 74.9 (C-5’’’), 78.2 (C-7a’’’), 99.5 (C-3a’’’), 113.8 (C-2’’’), 117.5 (C-
3’), 118.4 (C-1’), 119.0 (C-4), 120.2 (C-5’), 120.5 (C-α), 127.6 (C-5), 128.6 (C-2’’, 6’’), 
129.1 (C-β), 129.5 (C-6’), 129.6 (C-3’’, 5’’), 130.3 (C-4’), 133.2 (C-4’’), 137.4 (C-1’’), 
149.2 (C-3), 156.8 (C-2’), ppm.  
1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-hydroxymethyl-2-methyltetrahydro-5H-
[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-hydroxyphenyl)-4-(2-trifluoromethylstyryl)-
1H-pyrazole (8b) 
Pale beige solid, m.p. 75.1-76.1 ºC, 66%. 
1H NMR [(CD3)2CO, 500.16 MHz]: δ = 2.13 (s, 3 H, 2’’’-CH3) 
3.66 (dd 1 H, J = 8.9, 4.4 Hz, H-6’’’), 3.73 (t, 1 H, J = 5.6 Hz, 
CH2OH), 3.78 (dd, 1 H, J = 5.6, 2.3 Hz, H-5’’’), 3.86 (dd, 1 H, J = 
11.2, 2.3 Hz, CH2OH), 4.03 (t, 1 H, J = 4.4 Hz, H-7’’’), 4.31 (t, 1 H, 
J = 4.8 Hz, H-7a’’’), 5.97 (d, 1 H, J = 4.8 Hz, H-3a’’’), 6.96 (ddd, 1 
H, J = 7.5, 7.7, 1.1 Hz, H-5’), 7.02 (dd, 1 H, J = 8.2, 1.1 Hz, H-3’), 
7.27-7.37 (m, 1 H, H-4’), 7.30 (d, 1 H, J = 16.0 Hz, H-α), 7.31 (d, 1 
H, J = 16.0 Hz, H-β), 7.50 (t, 1 H, J = 7.8 Hz, H-4’’), 7.64 (dd, 1 H, J = 7.7, 1.6 Hz, H-6’), 
7.68 (t, 1 H, J = 7.8 Hz, H-5’’), 7.75 (d, 1 H, J = 7.8 Hz, H-3’’), 7.95 (d, 1 H, J = 7.8 Hz, 
H-6’’), 8.43 (s, 1 H, H-5) ppm.       
13C NMR [(CD3)2CO, 75.47 MHz]: δ = 25.0 (2’’’-CH3), 63.0 (CH2OH), 70.4 (C-6’’’), 
73.8 (C-7’’’), 74.9 (C-5’’’), 78.3 (C-7a’’’), 99.6 (C-3a’’’), 113.9 (C-2’’’), 117.5 (C-3’), 
118.4 (C-1’), 118.8 (C-4), 120.2 (C-5’), 124.2 (C-α), 127.9 (C-5), 128.2 (C-6’’), 128.3 (C-
4’’), 129.6 (C-6’), 130.4 (C-4’, β), 133.4 (C-5’’), 137.4 (C-1’’), 149.5 (C-3), 156.7 (C-2’), 
ppm.  
MS (ESI+) m/z (%): 535.2 [(M+H)+, 100].  
HRMS (ESI+) m/z calcd for C26H25F3N2O7 (M+H)
+, 535.1677; found: 535.1687. 
 
Note: It was not possible to unequivocally assign the resonance of C-2’’, C-3’’ and CF3 
carbons.  
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5.2.5.  Synthesis of the complexes [Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-styryl-
1H-pyrazole)(DMSO)Cl]Cl 
The procedure employed for the synthesis of the complexes of ruthenium and 
pyrazoles was adopted from Silva et al.20 To a solution of compound 4 (0.22 mmol) in 25 
mL of MeOH, it was added 0.8 equiv. of Ru([9]anesS3)(DMSO)Cl2 (75 mg, 0.17 mmol). 
The reaction mixture was refluxed under nitrogen, at 60 ºC and constant stirring for 18h. 
After that period, the obtained solution was evaporated until one-third of the initial volume 
of methanol was left. To that solution, a large volume of diethyl ether was added. To aid 
the formation of the precipitate, the solution was kept under a cool temperature using ice. 
Whenever the precipitation process was concluded, the solid was filtered, washed with 
diethyl ether and immediately dried in the vacuum pump. The desired complexes 9a-d 
were obtained as yellow solids, with 30 %, 72 % and 51% of yield. The yield of the 
complex 9d was not calculated. Depending on the solubility of the compounds, some 
precipitates were easier to form than others. For that reason, for obtaining the precipitates 
of 9a and 9d it was necessary to resort to liquid nitrogen to cool down the solution. 
 [Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazole)(DMSO)Cl]Cl (9a) 
Yellow solid, 30%. 
1H NMR [DMSO-D6, 500.16 MHz]§: δ = 2.57-2.85 (m, 12 
H, CH2, [9]aneS3), 2.95-3.06 (m, 6 H, 2 × CH3, DMSO), 
6.91-6.98 (m, 2 H, H-3’*,5’*), 7.00-7.05 (m, 1 H, H-5’), 
7.03 (d, 1 H, J = 16.2 Hz, H-α), 7.07-7.08 (m, 1 H, H-3’), 
7.10 (d, 1 H, J = 16.2 Hz, H-β), 7.19-7.31 (m, 4 H, H-
4’,4’*,4’’,4’’*), 7.33-7.36 (m, 2 H, H-3’’*,5’’*), 7.38 (t, 2 
H, J = 7.6 Hz, H-3’’,5’’), 7.40 (dd, 1 H, J = 8.1, 1.8 Hz, H-
                                                          
§ The “*” symbol present in the complexes 9a-d NMR characterization indicates the resonance of 
the protons correspondent to the less abundant complex. The stereochemistry depicted for 
complexes 9a-d is merely representative. 
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6’*), 7.50 (d, 2 H, J = 7.4 Hz, H-2’’*,6’’*), 7.52 (dd, 1 H, J = 7.8, 1.6 Hz, H-6’), 7.55 (d, 2 
H, J = 7.6 Hz, H-2’’,6’’), 8.29 (d, 1 H, J = 2.0 Hz, H-5), 8.34 (d, 1 H, H-5*), 10.65 (s, 1 H, 
2’-OH*), 10.90 (s, 1 H, 2’-OH), 12.90 (s, 1 H, NH*), 12.93 (s, 1 H, NH) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
13C NMR [DMSO-D6, 75.47 MHz]: δ = 30.1-35.2 (CH2, [9]aneS3), 114.1 (C-1’), 114.5 
(C-1’*), 116.3 (C-3’,3’*), 117.3-120.0 (C-4,4*,5’,5’*,α,α*), 125.7 (C-2’’*,6’’*), 126.2 (C-
2’’,6’’), 127.5 (C-4’’*), 127.7 (C-4’’), 128.7 (C-β*), 128.8 (C-β), 128.9 (C-
3’’,3’’*,5’’,5’’*), 129.8 (C-6’), 130.0 (C-6’*), 130.6 (C-4’*), 130.9 (C-4’*), 137.0 (C-
1’’*), 137.1 (C-1’’), 138.9 (C-3*), 139.0 (C-3), 140.6 (C-5*), 141.3 (C-5), 154.8 (C-2’, 
2’*) ppm.  
FT-IR (KBr, ν̄max (cm-1)): 2961 m (νC–H macro), 2921 s (νC–H macro), 1635 m (νC=N), 
1108 vs (νC–OH), 967 m (ωCα=Cβ), 908 m (ρC–H (DMSO)), 826 m (ρC–H (DMSO)),  
760 vs (νC–H), 697 vs (νC–H), 493 w (νRu–S (macro)), 425 m (νRu–S (DMSO)), 377 w 
(νRu-N). 
MS (ESI+) m/z (%): 657.1 (M+, 100). 
Anal. Calcd. for (Ru(C6H12S3)(C17H14N2O)(C2H6SO)Cl2)·0.3H2O (698.2) (%): C, 43.01; 
H, 4.706; N, 4.012; S, 18.37. Found: C, 43.05; H, 4.632; N, 4.031; S, 16.14. 
[Ru([9]aneS3)((E)-4-(4-chlorostyryl)-3(5)-(2-hydroxyphenyl)-1H-
pyrazole)(DMSO)Cl]Cl (9b) 
Yellow solid, 72%. 
1H NMR [DMSO-D6, 500.16 MHz]: δ = 2.59-2.88 (m, 12 
H, CH2, [9]aneS3), 2.91-3.10 (m, 6 H, 2 × CH3, DMSO), 
6.89-6.98 (m, 2 H, H-3’*,5’*), 7.01 (t, 1 H, J = 7.6 Hz, H-
5’), 7.04-7.11 (m, 1 H, H-3’), 7.08 (d, 1 H, J = 16.2 Hz, H-
α), 7.23 (d, 1 H, J = 16.2 Hz, H-β), 7.26-7.41 (m, 2 H, H-
4’,4’*), 7.43 (d, 2 H, J = 8.5 Hz, H-3’’,5’’), 7.51 (dd, 1 H, J 
= 7.6, 1.4 Hz, H-6’), 7.57 (d, 2 H, J = 8.5 Hz, H-2’’,6’’), 
8.30 (d, 1 H, J = 1.9 Hz, H-5), 8.33 (d, 1 H, J = 1.3 Hz, H-5*), 10.65 (s, 1 H, 2’-OH*), 
10.90 (s, 1 H, 2’-OH), 12.91 (s, 1 H, NH*), 12.95 (s, 1 H, NH) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
13C NMR [DMSO-D6, 75.47 MHz]: δ = 30.2-35.2 (CH2, [9]aneS3), 114.1 (C-1’*), 116.1 
(C-1’), 116.3 (C-3’,3’*), 118.2  (C-α), 118.5 (C-α*), 118.8 (C-4*), 119.2 (C-4), 119.7 (C-
5’*), 119.9 (C-5’), 127.8 (C-2’’*,6’’*), 127.9 (C-2’’,6’’), 128.7 (C-β), 128.8 (C-
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3’’,3’’*,5’’,5’’*), 129.9 (C-6’), 130.1 (C-6’*), 130.7 (C-4’*), 130.9 (C-4’), 131.7 (C-4’’*), 
131.2 (C-4’’), 136.0 (C-1’’), 136.1 (C-1’’*), 139.1 (C-3*), 139.2 (C-3), 140.7 (C-5*), 
141.4 (C-5), 154.8 (C-2’, 2’*) ppm.  
FT-IR (KBr, ν̄max (cm-1)): 2961 m (νC–H macro), 2926 s (νC–H macro), 1639 m (νC=N), 
1108 s (νC–OH), 967 m (ωCα=Cβ), 909 m (ρC–H (DMSO)), 826 m (ρC–H (DMSO)), 759 
m (νC–H), 686 m (νC–H), 455 w (νRu–S (macro)), 425 m (νRu–S (DMSO)), 373 w (νRu-
N). 
MS (ESI+) m/z (%): 693.0 (M+, 37Cl) (100), 691.0 (M+, 35Cl).  
Anal. Calcd. for (Ru(C6H12S3)(C17H13N2OCl)(C2H6SO)Cl2) (727.2) (%): C, 41. 32; H, 
4.304; N, 3.858; S, 17.61. Found: C, 42.13; H, 4.607; N, 4.057; S, 15.48.   
[Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-(2-trifluoromethylstyryl)-1H-
pyrazole)(DMSO)Cl]Cl (9c) 
 
Yellow solid, 51%. 
1H NMR [DMSO-D6, 500.16 MHz]: δ = 2.59-2.86 (m, 12 
H, CH2, [9]aneS3), 2.88-3.04 (m, 6 H, 2 × CH3, DMSO), 
6.90-6.91 (m, 1 H, H-3’*), 6.94 (t, 1 H, J = 7.5 Hz, H-5’*), 
6.98 (t, 1 H, J = 7.5 Hz, H-5’), 7.03 (d, 1 H, J = 15.8 Hz, H-
β), 7.06-7.07 (m, 1 H, H-3’), 7.10 (d, 1 H, J = 15.8 Hz, H-α), 
7.24 (d, 1 H, J = 15.7 Hz, H-α/β*), 7.30-7.36 (m, 2 H, H-
4’,4’*), 7.49 (t, 1 H, J = 7.7 Hz, H-4’’), 7.46 (d, 1 H, J = 7.5, 
H-6’), 7.61-7.64 (m, 1 H, H-5’’*), 7.67 (t, 1 H, J = 7.7 Hz, H-5’’), 7.71 (d, 1 H, J = 8.0 Hz, 
H-3’’*), 7.73 (d, 1 H, J = 7.7 Hz, H-3’’), 7.83 (d, 1 H, J = 8.0 Hz, H-6’’*), 7.89 (d, 1 H, J 
= 7.7 Hz, H-6’’), 8.30 (d, 1 H, J = 1.9 Hz, H-5), 8.32 (d, 1 H, H-5*), 10.58 (s, 1 H, 2’-
OH*), 10.80 (s, 1 H, 2’-OH), 13.09 (s, 1 H, NH), 13.10 (s, 1 H, NH*) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
13C NMR [DMSO-D6, 75.47 MHz]: δ = 30.3-35.1 (CH2, [9]aneS3), 114.0 (C-1’*), 114.3 
(C-1’), 116.3 (C-3’,C-3’*), 118.1 (C-4*), 118.7 (C-4), 119.5 (C-5’*), 119.6 (C-5’), 112.5 
(C-α), 122.9 (C-β), 124.2 (C-α/β*), 127.1 (C-6’’*), 127.4 (C-6’’), 127.6 (C-4’’*), 127.8 
(C-4’’), 130.1 (C-6’), 130.4 (C-6’*), 130.8 (C-4’*), 131.0 (C-4’), 132.8 (C-5’’*), 132.9 (C-
5’’), 135.7 (C-1’’*), 135.8 (C-1’’), 140.0 (C-3*), 140.2 (C-3), 140.9 (C-5*), 141.7 (C-5), 
155.0 (C-2’*), 155.1 (C-2’*) ppm.  
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FT-IR (KBr, ν̄max (cm-1)): 2923 m (νC–H macro), 1637 m (νC=N), 1107 vs (νC–OH), 965 
m (ωCα=Cβ), 910 w (ρC–H (DMSO)), 829 w (ρC–H (DMSO)),762 m (νC–H), 682 m 
(νC–H), 425 m (νRu–S (DMSO)), 375 w (νRu-N). 
MS (ESI+) m/z (%): 725.1 (M+, 100).  
Anal. Calcd. for (Ru(C6H12S3)(C18H13N2OF3)(C2H6SO)Cl2)·0.2H2O (764.4) (%): C, 40.85; 
H, 4.140; N, 3.665; S, 16.78. Found: C, 40.91; H, 4.134; N, 3.831; S, 15.97. 
  
Note: It was not possible to unequivocally assign the resonances of C-2’’, C-3’’ and CF3 
carbons. 
 
[Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-(4-methoxystyryl)-1H-
pyrazole)(DMSO)Cl]Cl (9d) 
 
Yellow solid. 
1H NMR [DMSO-D6, 500.16 MHz]: δ = 2.59-2.87 (m, 12 
H, CH2, [9]aneS3), 2.95-3.14 (m, 6 H, 2 × CH3, DMSO),   
3.76 (s, 3 H, 4’’-OCH3*), 3.77 (s, 3 H, 4’’-OCH3), 6.84 (d, 1 
H, J = 16.3 Hz, H-α), 6.92 (d, 2 H, J = 8.9 Hz, H-3’’*,5’’*), 
6.95 (d, 2 H, J = 8.8 Hz, H-3’’,5’’), 6.99-7.05 (m, 1 H, H-
5’), 7.01 (d, 1 H, J = 7.8 Hz, H-3’*), 7.06 (d, 1 H, J = 7.9 
Hz, H-3’), 7.17 (d, 1 H, J = 16.3 Hz, H-β), 7.28 (dt, 1 H, J = 
7.8, 1.4 Hz, H-4’*), 7.32 (ddd, 1 H, J = 7.9, 7.8, 1.3 Hz, H-4’), 7.41 (dd, 1 H, J = 7.8 Hz, 
H-6’*), 7.44 (d, 2 H, J = 8.9 Hz, H-2’’*,6’’*), 7.49 (d, 2 H, J = 8.8 Hz, H-2’’,6’’), 7.53 
(dd, 1 H, J = 7.8, 1.3 Hz, H-6’), 8.24 (d, 1 H, J = 2.1 Hz, H-5*), 8.26 (d, 1 H, J = 1.9 Hz, 
H-5), 10.65 (s, 1 H, 2’-OH*), 10.90 (s, 1 H, 2’-OH), 12.85 (s, 1 H, NH*), 12.90 (s, 1 H, 
NH) ppm.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
13C NMR [DMSO-D6, 75.47 MHz]: δ = 30.1-35.2 (CH2, [9]aneS3), 55.1 (4’’-OCH3) 114.1 
(C-3’’*,5’’*), 114.2 (C-3’’,5’’), 114.9 (C-1’), 115.6 (C-α), 116.3 (C-3’,3’*), 118.9 (C-4), 
119.6 (C-4*), 119.7 (C-5’), 119.8 (C-5’*), 127.4 (C-2’’*,6’’*), 127.5 (C-2’’,6’’), 128.8 (C-
1’’), 129.6 (C-6’*), 129.8 (C-6’), 129.9 (C-β), 130.4 (C-4’), 130.7 (C-4’*), 138.4 (C-3), 
138.6 (C-3*), 140.3 (C-5*), 141.0 (C-5), 154.7 (C-2’,2’*), 158.8 (C-4’’), 158.9 (C-4’’*) 
ppm.  
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FT-IR (KBr, ν̄max (cm-1)): 2966 m (νC–H macro), 2926 m (νC–H macro), 1605 m (νC=N), 
1110 m (νC–OH), 966 m (ωCα=Cβ), 908 m (ρC–H (DMSO)), 822 m (ρC–H (DMSO)),   
760 m (νC–H), 687 m (νC–H), 493 w (νRu–S (macro)), 457 w (νRu–S (macro)), 424 m 
(νRu–S (DMSO)), 373 w (νRu-N). 
MS (ESI+) m/z (%): 687.1 (M+, 100).  
Anal. Calcd. for (Ru(C6H12S3)(C18H16N2O2)(C2H6SO)Cl2) (722.8) (%): C, 43.21; H, 
4.741; N, 3.876; S, 17.74. Found: C, 43.38; H, 4.747; N, 4.090; S, 15.40. 
5.2.6.  Biological assays 
5.2.6.1. Preparation of the stock solutions 
 
All the stock solutions were freshly prepared in 100% DMSO, at a concentration of 
20 mM. Since DMSO is toxic to cells at certain concentrations,100 the dilutions, which 
were performed with the appropriate cell culture medium, were arranged so that the 
maximum concentration of DMSO in each well was 0.5% (v/v). Parallel experiments, 
which are not presented here, revealed that the cell viability was not compromised upon 
exposure to 0.5% (v/v) DMSO for both cell lines studied.     
5.2.6.2. Thaw of the cell lines 
 
The cell lines, which were provided by the Faculty of Pharmacy of University of 
Porto, were preserved at –80 ºC. The thaw of the cells was accomplished by resuspending 
them in 45 mL of previously heated culture medium at 37 ºC. Then, a centrifugation at 210 
g was performed for 5 minutes, at 37 ºC. The supernatant was discarded and the pellet was 
resuspended in 15 mL of culture medium at 37 ºC. This volume was added to a 75 cm2 
flask, where the cells where allowed to grow, as intended.  
5.2.6.3. Cell culture 
  
Two human cell lines were tested in the present work: the human lung fibroblast 
cell line (MRC-5) and the human gastric adenocarcinoma cell line (AGS). The cells were 
cultured as monolayers and maintained at 37 ºC, in a humidified incubator under 5% of 
CO2. The AGS cancer cell line was maintained in DMEM (1X) + GlutaMAX™-1 
(Dulbecco’s Modified Eagle Medium) and the MRC-5 cell line was maintained in MEM 
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(1X) + GlutaMAX™-1 (Minimum Essential Medium). Each culture medium was 
previously supplemented with 10% of FBS (fetal bovine serum) and 1% of penicillin-
streptomycin. 
Whenever the cells reached 80% of confluence, the cell culture medium was 
rejected and the 75 cm2 flask was washed twice with 8 mL of PBS (phosphate-buffered 
saline). Afterwards, 2.5 mL of trypsin (0.25%) were added and the flask was placed in the 
incubator for 3 minutes. After that period, 5 mL of the proper culture medium was added 
and the obtained mixture was transferred to a centrifuge tube and centrifuged for 3 
minutes, at 1300 rpm and 37 ºC. The supernatant was discarded and the pellet was 
resuspended in 4 mL of culture medium. The desired volume of this mixture was then 
transferred to a new 75 cm2 flask, already containing 13 mL of the adequate culture 
medium. 
The number of cells was assessed by transferring 10 μL of the solution of the 
resuspended cells in 4 mL of culture medium to an eppendorf with 90 μL of trypan blue. 
The number of cells was counted resorting to a Neubauer chamber. 
5.2.6.4. MTT assay 
The assessment of the cytotoxic activity of the compounds was performed by the 
MTT assay. This colorimetric assay is widely used to quantify the cell viability.101 This 
assay is based on the reduction of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] into the insoluble purple formazan. The reduction of MTT is 
caused by the enzymatic activity of the mitochondria, via the cleavage of the tetrazolium 
ring (see Scheme 4.1).  
 
Scheme 4.1 – Mitochondrial reduction of MTT to formazan, adapted from Präbst et al.101 
The formed formazan crystals are impermeable to cell membranes, so, they hoard inside 
the viable cells. Therefore, the amount of formazan crystals is a good marker for the 
95 
 
cellular viability. After solubilization, the formazan is spectrophotometrically measured at 
its absorbance maximum (570 nm). 
The MTT assay was performed following the adaptation of Videira et al.102 The 
cells were plated at the density of 1.5 × 104 cells/cm2 for AGS and 2.0 × 104 cells/cm2 for 
MRC-5, in 96-well microplates. After 24 hours, the culture medium of the wells was 
aspirated and 100 μL of the proper compound dilution was added in triplicate. The 96-well 
microplates were incubated at 37 ºC and 5% of CO2 for 24 hours. After that period, the 
solutions of the testing compounds were removed and a solution of 100 μL of MTT:culture 
medium (1:10) was added to each well. After 2 hours of incubation, the MTT:culture 
medium solution was removed and the formed formazan was dissolved in 200 μL of 
DMSO:isopropanol (3:1). The optical absorbance was measured at 570 nm, using a 
microplate reader Thermo Scientific™ Multiskan™ GO. 
5.2.6.5. Statistical analysis 
 The statistical analysis of the cell viability data was made using the GrapPad 
Prism® 6 software. The measured absorbance was converted into percentage of cell 
viability relative to the control, according to the formula presented in the Equation 5.1. The 
OD sample is the absorbance measure for wells containing drug-treated cells and the OD 
control represents the absorbance measured for the wells with untreated cells. The 
percentage of cell viability of the control was calculated as seen in the Equation 5.2, where 
?̅? OD control represents the mean of the absorbance measured for the wells with untreated 
cells.   
OD sample
OD control
 × 100 
OD control
?̅? OD control
 × 100 
The results (chapter 4) are expressed as the mean ± mean standard deviation 
obtained from three to four independent experiments, each comprising three replicate 
(5.1) 
(5.2) 
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measurements performed for each concentration of each compound tested, plus the 
untreated control.  
The significant outliers of the cell viability data were excluded resorting to Grubb’s 
test, also known as the extreme studentized deviate method from GraphPad. The 
distribution of the data was evaluated by the D’Agostino-Pearson normality test. 
According to this test, the cell viability data for both AGS and MRC-5 cell line presented a 
normal distribution. The statistical analysis was performed by one-way ANOVA, followed 
by the Dunnetts’s post hoc test for statistical comparison between the experimental data, 
the p-values minor than 0.05 were deemed significant.  
The IC50 values were determined by fit spline, using the method point-to-point to 
create a curve. To avoid redundancy the curves were not shown in this work.  
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Conclusions and future perspectives 
 
The glycosylation of (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 4a-d via 
the Koenigs-Knorr reaction afforded new (E)-1-[β-D-(2,3,4,6-tetra-O-acetylglycose-1-yl)]-
3-(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 5a-d, and 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-
diacetoxy-5-acetoxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-
(2-hydroxyphenyl)-4-styryl-1H-pyrazoles 6a-d. Generally, compounds 6 were the main 
reaction product. However, the yield of compounds 6 was particularly affected by the 
presence of water in the reaction solvent – dichloromethane. The global yield of the 
glycosylation reaction is increased when dichloromethane is dried over calcium hydride, 
distilled and kept stored with molecular sieves. Furthermore, longer reaction times (10 
days) also seem to increase the global yield of the glycosylation reaction.  
The cleavage of the acetyl protecting groups of the sugar moiety of compounds 5 
and 6 resulted in the novel compounds (E)-1-[β-D-(glycose-1-yl)]-3-(2-hydroxyphenyl)-4-
styryl-1H-pyrazoles 7a-d and compounds 1-[(2R,3aR,5R,6S,7S,7aR)-6,7-dihydroxy-5-
hydroxymethyl-2-methyltetrahydro-5H-[1,3]dioxolo[4,5-b]pyran-2-yl]-(E)-3-(2-
hydroxyphenyl)-4-styryl-1H-pyrazoles 8a,b. The structure of all the mentioned compounds 
was determined by 1D and 2D NMR techniques and by mass spectrometry. These analyses 
disclosed that all the obtained products are N-glycosylated.  
The Ru[9]aneS3 coordination with (E)-3(5)-(2-hydroxyphenyl)-4-styryl-1H-
pyrazoles afforded the novel complexes [Ru([9]aneS3)((E)-3(5)-(2-hydroxyphenyl)-4-
styryl-1H-pyrazole)(DMSO)Cl]Cl 9a-d. The purity and structure of the ruthenium-
pyrazoles was determined by 1D and 2D NMR techniques, infrared spectroscopy (FT-IR), 
mass spectrometry and elemental analysis. Coordination of the pyrazole derivatives to 
ruthenium occurred via the replacement of one chloride rather than the DMSO, as 
confirmed by the mass spectrometry results, NMR and FT-IR. 
The cytotoxic activity of compounds 4a-d, 7a-c, 8a,b and 9a-d was evaluated by 
the MTT colorimetric assay on the cancer AGS and healthy MRC-5 cell lines. The most 
potent compounds against the AGS cancer cell line are 4b and 9d with IC50 values of 37.0 
and 18.3 μM, respectively. Among these two compounds, 4b has less selectivity than 9d. 
In fact, compound 4b presents high cytotoxicity against the MRC-5 cell line (IC50 = 45.0 
μM) and, consequently, it has a narrow safety margin. Complex 9d has an IC50 value of 
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62.2 μM against MRC-5 cell line, which is approximately three-fold higher than the one 
obtained against the AGS cancer cell line. Complex 9d is more selective than the pure 
ligand, 4d, which suggests that the Ru coordination improves the selectivity. The insertion 
of a sugar moiety into the pyrazole scaffold also increased the selectivity of the compounds 
when compared to their precursors. Concerning the cytotoxic activity, the insertion of the 
sugar moiety was beneficial for the ortho-CF3 compounds but jeopardized the cytotoxic 
activity of the para-Cl compounds. In the future, it is appropriate to finish the studies for 
the remaining compounds against the MRC-5 cell line. Also, the compounds should be 
tested against other cancer and healthy cell lines.  
Hereafter, it is also worth exploring the effect of an electron-donating group in the 
phenyl ring of the glycosylated products and to test the influence of the substituent position 
by synthetizing these glycosylated products substituted with -ortho-Cl or -para-CF3 in the 
phenyl ring. Furthermore, it is also envisioned to expand the Ru([9]aneS3)(pyrazole) 
family by substituting the phenyl ring with other electron-donating groups.  
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